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Abstract
Growing evidence from the last decades intimately links obesity with insulin resistance
and type 2 diabetes mellitus as a consequence. Thus, the role of the central nervous sys-
tem and especially the hypothalamus in the control of energy homeostasis are intensively
investigated. The melanocortin system has been identified as a pivotal neurocircuit in
this homeostatic process, but many other neuronal populations are similarly involved.
Furthermore, the role of insulin as adiposity signal in the control of energy homeostasis
has to be further clarified. In particular, steroidogenic factor 1 (SF-1)-expressing neu-
rons of the ventromedial hypothalamus (VMH) control energy homeostasis, but the role
of insulin action in these cells remains undefined. This study shows that insulin acti-
vates phosphatidylinositol-3-kinase (PI3K) signaling in SF-1 neurons and reduces firing
frequency in these cells by the activation of ATP-dependent potassium (KATP) channels.
These effects were abrogated in mice with Cre-mediated insulin receptor deficiency re-
stricted to SF-1 neurons (SF-1∆IR mice). Whereas body weight and glucose homeosta-
sis remained the same in SF-1∆IR mice as in controls on a normal chow diet, they were
protected from diet-induced leptin resistance, weight gain, adiposity and impaired glu-
cose tolerance. High-fat feeding activated PI3K signaling in SF-1 neurons of control
mice, and this response was attenuated in the VMH of SF-1∆IR mice. Mimicking diet-
induced overactivation of PI3K signaling by disruption of the phosphatidylinositol-3,4,5-
trisphosphate phosphatase PTEN led to increased body weight and hyperphagia under
normal chow diet conditions. Collectively, this study reveals that high-fat diet–induced,
insulin-dependent PI3K activation in VMH neurons contributes to obesity development.
Additionally, insulin was identified as a necessary signal in SF-1 VMH neurons in-
volved in the induction of the counter-regulatory response to hypoglycemia, one of the
major limitations for insulin treatment in diabetic patients.
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Zusammenfassung
Zunehmende Erkenntnisse der letzten Jahrzehnte konnten zeigen, dass Übergewicht und
Insulin Resistenz, mit Typ 2 Diabetes Mellitus als Folge, stark assoziierte Zustände sind.
Deshalb werden die Rolle des zentralen Nervensystems und speziell des Hypothalamus
in der Kontrolle der Energie Homöostase intensiv erforscht. Das Melanokortin System in-
nerhalb des Hypothalamus wurde als zentrales neuronales Netzwerk für diesen homöo-
statischen Prozess identifiziert. Die Effekte von Insulin als Sättigungssignal innerhalb
des Gehirns waren ebenfalls Gegenstand der Forschung der letzten Jahre. Des weit-
eren wurden Steroidogenic Factor 1 (SF-1) exprimierende Neuronen innerhalb des ven-
tromedialen Hypothalamus (VMH) als beteiligte Neuronenpopulation in der Kontrolle
der Energie Homöostase identifiziert, jedoch wurde die Rolle des Insulinsignalwegs in
diesen Zellen bisher noch nicht erforscht. Die vorliegende Arbeit konnte zeigen, dass
Insulin in SF-1 Neuronen den Phosphatidylinositol-3-kinase (PI3K) Signalweg stimuliert
und damit die Aktivität dieser Neurone durch das Steuern von ATP-abhängigen Kalium
(KATP) Kanälen herabsetzt. Dieser Effekt war in Mäusen denen der Insulinzezeptor in
SF-1 exprimierenden Neuronen fehlt (SF-1∆IR) nicht mehr vorhanden. Diese Defizienz
hatte unter normalen Fütterungsbedingungen keine Auswirkungen, wurden die Mäuse
jedoch mit einer fettreichen Diät gefüttert, waren SF-1∆IR Tiere zum Teil vor Ernährungs-
bedingter Gewichtszunahme, Leptinresistenz, Fettleibigkeit und Glukoseintoleranz geschützt.
Die Deletion der PI3K-spezifischen Phosphatidylinositol-3,4,5-trisphosphate Phosphatase
PTEN dagegen führte zu Übergewicht und Hyperphagie unter Normal-Futter Bedin-
gungen, da die durch fettreiche Ernährung bedingte Überaktivierung der PI3K imitiert
wird. Zusammenfassend konnte wurde gezeigt, dass die ernährungs-bedingte Überak-
tivierung der PI3K in VMH SF-1 Neuronen zur Entwicklung von Übergewicht beiträgt.
Des Weiteren konnte gezeigt werden, dass der Insulinsignalweg in SF-1 Neuronen für
die Aktivierung der Leber-spezifischen Glukoneogenese zur Verhinderung von Hypo-
glykämie, welches eine der Hauptkomplikationen der Insulintherapie darstellt, notwendig
ist.
xii
1 Introduction
1.1 Obesity
Energy homeostasis in the body is a tightly regulated process. In order to maintain an
adequate body weight, energy intake and energy expenditure are kept in balance. Obe-
sity, in contrast, is the consequence of a sustained positive energy balance. That means
to consume more calories than an organism is spending, resulting in excessive storage of
lipids in the expanded adipose tissue.
From an evolutionary perspective, obesity is actually a favorable condition. To store
energy in the form of adipose tissue in good and plentiful times in order to survive peri-
ods of deprivation or starvation has almost exclusively benefits for the organism. Espe-
cially for seasonal active animals these energy depots are mandatory and the only way
to survive the winter or other deprivation periods.
Also for humans these facts hold true, but the living conditions have changed dramat-
ically in the last centuries. The availability of food has increased due to the industrial
revolution and the globalization of our society, resulting in the disappearance of food
deprivation (at least in the highly developed countries). Additionally, the energy density
of the available food has increased massively over the last decades. In the 1970s in the
USA, the average caloric intake per day was 2234 calories. Until 2003 it has raised to 2757
calories per day, an increase of almost 25 percent (Hodan & Buzby, 2005).
Besides, a more sedentary lifestyle in western societies with reduced physical work
further contributes to a positive energy balance. As a net effect of the above mentioned
factors, the average body mass index (BMI) in Europe and the USA has increased over the
last 40 years, resulting in an obesity rate of 40 percent (defined by a BMI of above 30) in
the USA and more than 30 percent in Europe (Berghöfer et al. , 2008). Worldwide, the total
number has risen to 1.4 billion overweight (defined as a BMI above 25) and 200 million
obese people (WHO, 2012). This sustained obesity is associated with a risk to develop
severe metabolic disorders, such as Type 2 Diabetes Mellitus (T2DM) and cardiovascular
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diseases, and it also pre-disposes for other diseases such as cancer, osteoarthritis, non-
alcoholic fatty liver disease and obstructive sleep apnea (Dixon, 2010; Mokdad et al. ,
2003). The overall health costs caused by obesity-associated disorders already exceeded
10 billion e in 2008 and the World Health Organization estimates that every year 2.8
million adults die as a consequence of being obese or overweight (WHO, 2012). Thus,
obesity is already considered a pandemic of the 21st century and is a major health burden
in the western civilizations.
1.2 Regulatory Mechanism of Energy Homeostasis
In a healthy subject the caloric intake is adjusted and adapted to the amount of used
energy and the current storage status of the body. Vice versa, the expended energy is also
adapted to the food availability and nutrient status, assuming a regulatory signal from
the body, that reflects its energy status to the brain. This has been proposed more than 40
years ago (Coleman, 1973; Coleman & Hummel, 1969), and research in the last decades
verified this hypothesis by the discovery of several peripheral hormones involved in this
regulatory process (Bataille et al. , 1981; Brüning et al. , 2000; Kojima et al. , 1999; Lacquaniti
et al. , 2011; Orskov et al. , 1994; Tatemoto & Mutt, 1980; Zhang et al. , 1994).
One of the major regulators in this homeostatic process is the anorectic hormone lep-
tin. It is mainly produced by adipocytes in the white adipose tissue (Margetic et al. , 2002).
This hormone reflects the amount of stored energy in the form of fat to the brain, which
then integrates this information and adjusts food consumption and energy expenditure to
the current needs (Friedman, 1998). However, due to the beforehand mentioned changes
in modern lifestyle, in millions of humans these regulatory mechanism fail, resulting in
overweight and finally in chronic obesity (Considine et al. , 1996).
Upon its discovery, leptin was assumed to be the ultimate cure for obesity (Campfield
et al. , 1996). But just a few years later the disillusioning discovery was made that obese
patients actually have massively increased circulating leptin levels compared to lean pa-
tients (Considine et al. , 1996), indicating that these obese subjects are leptin resistant
(Heymsfield et al. , 1999). Thus, except for a very few people carrying a mutation in their
endogenous Leptin gene, leptin alone is not suitable as therapeutic treatment for obese
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humans (Farooqi & O’Rahilly, 2004). But in combination with other peptide hormones,
such as Amylin, it is possible to restore leptin sensitivity and hence enable a leptin medi-
ated weight loss (Roth et al. , 2008). Although leptin resistance was discovered more than
a decade ago, it is still unclear which exact mechanisms or signaling pathways lead to the
development of leptin resistance. It has become obvious that both the transport across
the blood-brain barrier (BBB) to the brain and the intracellular signaling are impaired
(El-Haschimi et al. , 2000).
In addition to leptin, various other hormones are involved in this regulatory process,
such as insulin and ghrelin. The pancreatic hormone insulin exerts many of its effects in
the periphery, but also induces satiety when applied to the central nervous system (CNS)
(Blüher et al. , 2002; Brüning et al. , 1998; Michael et al. , 2000; Woods et al. , 1979). Fur-
thermore, insulin signaling in the brain plays a crucial role in maintaining energy home-
ostasis as well as reproduction (Brüning et al. , 2000; Hallschmid et al. , 2004; Havrankova
et al. , 1978b; Porte & Woods, 1981; Woods et al. , 1979). The best characterized hormone
stimulating food intake is ghrelin. It is mainly produced by the stomach and the gut
upon nutrient deprivation and likewise signals to the brain, leading to an increase in
food intake (Kojima et al. , 1999).
Eventually, it is the brain that orchestrates all these different hormonal signals and
furthermore draws the appropriate conclusions to adjust feeding and energy expenditure
to the current needs.
1.3 Neuronal Circuits in the Hypothalamus controlling Energy
Homeostasis
In the beginning of the twentieth century, obesity, as a feature of certain clinical symp-
toms, was discussed to result from either defects in the pituitary gland or in the CNS,
particularly the hypothalamus. The Fröhlich syndrome, a pituitary tumor, was a disease
pattern associated with obesity and hypogonadism, that pointed towards the pituitary
gland as main regulator of energy homeostasis (Fröhlich, 1901). The experiments of Het-
herington and Ranson finally ended this debate when they electrolytically lesioned the
hypothalamus of rats stereotactically without affecting the pituitary gland, resulting in
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morbidly obese animals (Hetherington & Ranson, 1940). These findings were further de-
fined by other groups in the following decades, using refined lesioning techniques for
their experiments. The Ventromedial Nucleus of the Hypothalamus (VMH) was spec-
ified as a satiety center, together with the Paraventricular Nucleus (PVN) (Gold, 1973;
Stevenson et al. , 1950). The VMH-derived signals were believed to be transmitted via
the abdominal vagus nerve by sympathetic and parasympathetic innervations to the in-
testinal tract, verified by the lesioning of the VMH with a simultaneous vagotomy of
the abdominal vagus nerve below the diaphragm. The subdiaphragmal vagotomy pre-
vented the effects of the VMH lesioning and the rats stayed lean and normophagic (Inoue
& Bray, 1977; Opsahl & Powley, 1974). In contrast, lesions in the Lateral Hypothalamus
(LH) led to hypophagia (Anand & Brobeck, 1951).
The role of the LH as feeding center was refined by lesion experiments with kainic
acid, but the exact role of certain neuronal populations remained elusive until the 1990s
(Grossman et al. , 1978; Stricker et al. , 1978). With the discovery of the LH specific hor-
mones orexin (ORX) and melanocyte concentrating hormone (MCH), the first neuropep-
tides were identified that increased their mRNA levels upon fasting (Bittencourt et al. ,
1992; de Lecea et al. , 1998; Sakurai et al. , 1998). Injection of these peptides into the brain
induced food intake and a knockout of MCH resulted in lean mice when compared to
controls, hence establishing the LH as phagic center in the hypothalamus (Qu et al. , 1996;
Sakurai et al. , 1998).
As mentioned earlier, the PVN, the VMH and the adjacent arcuate nucleus (ARC) were
defined as possible satiety centers. By systemic injections of toxic glucose analogs, the
ARC and the VMH were destroyed, resulting in hyperphagic and obese animals (Debons
et al. , 1962; Olney & Sharpe, 1969). Due to their location at the median eminence (ME),
which serves as the "window" of the BBB that can be passed by larger proteins (Broadwell
& Brightman, 1976), neurons in these areas are able to sense hormones and nutrients
from the periphery. Furthermore, the ARC and the VMH are in direct proximity of the
third ventricle, which exposes them to neuropeptides from the cerebrospinal fluid. The
discovery of leptin brought further insights into the hypothalamic regulation of energy
homeostasis, as intensive c-Fos immunoreactivity could be observed in the ARC after a
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peripheral injection of leptin (Elmquist et al. , 1997, 1998b; Van Dijk et al. , 1996; Woods &
Stock, 1996). Together with the targeted deletion of the melanocortin 4 receptor (MC4R),
the discovery of mutations in the MC4R in obese patients, the identification of its ligand
α-melanocyte stimulating hormone (α-MSH) and its antagonist agouti-related peptide
(AgRP) the ARC was established as primary center in the CNS-mediated regulation of
energy homeostasis (Fan et al. , 1997; Huszar et al. , 1997; Vaisse et al. , 1998).
LH	  
DMH	  
PVN	  
3V	  
ME	  
Figure 1.1: Schematic overview of hypothalamic nuclei.
Image taken from Allen mouse brain atlas (Allen institute for brain science, Seattle, USA). De-
picted are hypothalamic nuclei that are involved in the regulation of food intake, energy expen-
diture and substrate utilization. 3V, third ventricle; ARC, arcuate nucleus; DMH, dorsomedial
hypothalamic nucleus; LH, lateral hypothalamus; ME, median eminence; PVN, paraventricular
nucleus; VMH, ventromedial nucleus of the hypothalamus.
1.4 The Melanocortin System
The melanocortin system is a neurocircuitry that regulates energy balance. Of great im-
portance are neurons that are located in the ARC of the mediobasal hypothalamus (Fan
et al. , 1997). This region shows a high expression of receptors for various hormones in-
cluding leptin and insulin and lies in the direct proximity of the third ventricle and the
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median eminence, hence exposing it to signals from the cerebrospinal fluid (CSF) and
the circulation (Baskin et al. , 1993; Broadwell & Brightman, 1976; Elmquist et al. , 1998a;
Mercer et al. , 1996a,b; Obici et al. , 2002b; Wang et al. , 2002). Access to the latter one
is of critical importance for the aforementioned signals from the periphery. Two func-
tionally opposing neuronal populations are located in the ARC, which are the catabolic
anorexigenic Pro-opiomelanocortin (POMC) expressing neurons and the anabolic orexi-
genic Agouti-related Peptide (AgRP) expressing neurons (for review see Butler (2006)).
These two neuronal populations are first order neurons. They are able to sense hormones
such as leptin, insulin and ghrelin, but are also sensitive to changes in the level of blood
glucose and other metabolites and process these signals to other brain areas, leading to
an adaptation of thermoregulation, feeding and energy expenditure (Belgardt et al. , 2008;
Cowley et al. , 2001, 2003; Hill et al. , 2010; Kim et al. , 2000c; Mounien et al. , 2010; Nakazato
et al. , 2001).
POMC is translated as a precursor peptide, which gets cleaved in several steps by
cell type-specific pro-hormone convertases into the biologically active alpha-Melanocyte
Stimulating Hormone (α-MSH) and other neuropeptides (β-endorphin, β-MSH, γ-MSH
and ACTH) (Coll et al. , 2004; Millington, 2006). α-MSH can bind to MC4Rs, which are
G-protein coupled receptors, and thereby activate the adenylate cyclase, leading to an
increase of intracellular cyclic Adenosine Mono-Phosphate (cAMP) (Caruso et al. , 2012).
The release of α-MSH into the target areas of POMC neurons, such as the paraventricular
nucleus (PVN), and the binding to MC4Rs leads to a decreased food intake and an in-
creased energy expenditure (Giraudo et al. , 1998; Kim et al. , 2000a,b; Wirth et al. , 2001).
Although the further downstream mechanisms are still under investigation, most likely
thyrotropin releasing hormone (TRH) and corticotropin releasing hormone (CRH) pro-
ducing neurons in the PVN and in the dorsomedial hypothalamus (DMH) play a role
in the signal processing and further signal transduction (Kublaoui et al. , 2006; Lu et al. ,
2003; Sarkar et al. , 2002). These are brain areas in the direct proximity of the ARC, show
a high expression of MC4Rs and have been shown to be projection sites of POMC neu-
rons (Kim et al. , 2000a,b). Furthermore, mutations of the MC4R or POMC in humans is
highly associated with the development of morbid obesity, highlighting the pivotal role
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of POMC neurons and MC4Rs in the regulation of energy homeostasis (Coll et al. , 2004;
Farooqi et al. , 2000; Yeo et al. , 1998).
The opposing neuron populations in the ARC are the orexigenic AgRP expressing
neurons, that co-express neuropeptide Y (NPY). They inhibit POMC neurons in two dif-
ferent ways. On the one hand, by a direct inhibition of POMC neuron firing activity via
inhibitory GABAergic projections on POMC neurons, and on the other hand by an inhi-
bition of MC4Rs on their target neurons by the release of AgRP, which acts as a MC4R an-
tagonist (Aponte et al. , 2011; Atasoy et al. , 2012; Kim et al. , 2000b; Tang-Christensen et al.
, 2004). The latter mechanism seems to be the more important one, since a mutation in the
agouti gene, that results in an overexpression, leads to hyperphagic and obese mice (Ay)
(Ollmann, 1997). Latest electrophysiological and optogenetics experiments confirmed
these findings (Atasoy et al. , 2012). In contrast, NPY is expressed abundantly in the
brain. It is a potent stimulator of feeding, but its action does not seem to be limited to the
ARC and the melanocortin system (Sahu et al. , 1988; Stanley et al. , 1986).
The important role of POMC and AgRP neurons in the regulation of energy homeosta-
sis has been demonstrated by ablation experiments, where mice, carrying a transgenic
Diphtheria Toxin A (DTA)-receptor exclusively on AgRP or POMC neurons, were in-
jected with DTA to ablate these neurons. AgRP neuron ablated mice reduced their food
intake dramatically, leading eventually to death by starvation if not rescued by force-
feeding (Luquet et al. , 2005). In contrast, ablation of POMC neurons results in hyper-
phagia (Gropp et al. , 2005). Other experiments could show that AgRP neurons influence
locomotor behavior, e.g. by a constant activation of the Stat3 signaling pathway in AgRP
neurons of mice. These mice were leaner due to an increased locomotor activity in the
night phase (Mesaros et al. , 2008).
Besides the mere physiological effects on feeding and locomotor behavior, recent ev-
idence suggests that the melanocortin system is also connected to higher brain func-
tions, such as reward and addiction related behavior by direct and indirect connections
to dopaminergic neurons in the midbrain (Dietrich et al. , 2012).
Collectively, the melanocortin system has a pivotal role in the regulation of energy
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homeostasis, although higher brain functions, especially in humans, might be able to
overrule these signals (figure 1.2).
POMC AgRP
2nd order
neurons
White adipose tissue
Pancreas
Leptin Insulin
GABA
α-MSH
AgRP
GABA
Hepatic glucose
production
Food intake
MC4R
Energy
expenditure
Blood glucose
Hypothalamus
Figure 1.2: Schematic overview of the hypothalamic melanocortin system.
Adiposity signals, such as leptin and insulin are secreted in the periphery and transported across
the BBB to first order neurons in the hypothalamus, anorexigenic POMC and orexigenic AgRP
neurons. Both insulin and leptin on the one hand increase POMC transcription and firing rate of
POMC neurons and on the other hand inhibit AgRP transcription and activity of these neurons.
POMC neurons release their neurotransmitter α-MSH, that binds to MC4R on second order neu-
rons (e.g. in the PVN), and thereby stimulates energy expenditure and inhibits food intake and
hepatic glucose production. AgRP inhibits POMC neurons in two ways: by direct inhibition of
POMC neurons via GABAergic synapses and by GABA and AgRP, a MC4R antagonist, release to
second order neurons, leading to increased food intake, elevated hepatic glucose production and
reduced energy expenditure.
α-MSH, alpha-melanocyte stimulating hormone; AgRP, agouti-related peptide;
GABA, γ-aminobutyric acid; MC4R, melanocortin 4 receptor; POMC, pro-opiomelanocortin.
1.5 Leptin and Leptin Signaling
Leptin is a 16 kDa peptide hormone, mainly produced in the adipose tissue of mammals
and secreted into the circulation in proportion to the body fat content (Frederich et al. ,
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1995; Maffei et al. , 1995). Minimal expression was also reported in the placenta, skeletal
muscle, pancreas and some areas of the brain (Bado et al. , 1998; Masuzaki et al. , 1997).
It was discovered and cloned in 1994 as product of the obese gene (Zhang et al. , 1994).
A homozygous mutation in the obese gene leads to severe and morbid obesity amongst
the affected animals (Ingalls et al. , 1950). In parabiosis experiments, researchers were able
to curtail the mutation to a circulating hormone (Coleman, 1973; Coleman & Hummel,
1969; Harris, 1999). When an ob/ob mouse was parabiosed to a wildtype mouse, the ob/ob
mouse lost weight and eventually became lean as the wildtype mouse. The positional
cloning led to the discovery of the affected gene and its product leptin (greek: leptos =
lean) (Zhang et al. , 1994).
Leptin signals via its receptor, the leptin receptor (LepR), which belongs to the family
of class I cytokine receptors (Chua et al. , 1997). As with its ligand, the LepR was also
discovered by a spontaneous mutation in mice (Chen et al. , 1996; Tartaglia et al. , 1995).
Mice carrying the mutation were severely diabetic and obese, thus the gene was named
diabetes. When db/db mice were parabiosed to wildtype mice, the wildtype mice starved to
death due to the high circulating leptin concentrations derived from the massive amount
of adipose tissue in the db/db mouse (Coleman, 1973; Coleman & Hummel, 1969; Harris,
1999).
LepRs exist in different isoforms produced by alternative mRNA splicing, but only
its long form (LepRb) is able to induce an intracellular signaling cascade (Chen et al. ,
1996; Chua et al. , 1997; Tartaglia, 1997; Tartaglia et al. , 1995). As shown in a transgenic
complementation experiment, only the LepRb is able to rescue the phenotype of the db/db
mouse (Kowalski et al. , 2001). The role of the other isoforms is still under debate, but they
might play a role in the saturable transport across the BBB or in the clearance of leptin
from the circulation as soluble receptors (Hileman et al. , 2002; Uotani et al. , 1999).
When leptin binds to the LepRb, it induces an intracellular signaling cascade via the
JAK-STAT pathway (figure 1.3). Upon ligand binding, the receptor associated Janus Ki-
nase (JAK) 2 auto-phosphorylates itself and also phosphorylates the intracellular domain
of the receptor at multiple tyrosine residues (p-Tyr), which serve as binding sites for sig-
nal transducer and activator of transcription (STAT) proteins (in case of leptin: STAT3)
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(Tartaglia, 1997; White et al. , 1997). The STAT proteins are thereby phosphorylated, lead-
ing to their homo-dimerization, the exposure of a nuclear-localization domain and conse-
quently to the nuclear import, where STAT proteins can bind to the promotor of various
genes and exert their function (either repression or activation of transcription) (Banks
et al. , 2000; Boulton et al. , 1995; Lütticken et al. , 1994; Stahl & Yancopoulos, 1994). In
POMC neurons, leptin induced binding of STAT3 to the promotor of POMC is necessary
to activate transcription of the POMC gene and the deletion of STAT3 in POMC neurons
results in modest obesity and reduced POMC expression levels (Gao et al. , 2004; Xu et al.
, 2007).
Leptin exerts most, but not all, of its functions in the brain. The deletion of LepRs
in the brain leads to severe obesity, but does not reflect the complete phenotype of ob/ob
or db/db mice (Cohen et al. , 2001). The transgenic re-expression of LepRb in the brain is
sufficient, though, to partially or completely restore fat mass, food intake, reproductivity
and glucose tolerance in db/db mice, depending on the promotor that was used for the
transgene (de Luca et al. , 2005; Kowalski et al. , 2001). Together with the discovery of
the melanocortin system, POMC and AgRP neurons were thought to be the main target
for leptin, due to their role as first order neurons. But the deletion of the LepR in POMC
neurons resulted only in modest obesity (Balthasar et al. , 2004), and the same holds true
for the AgRP neuron specific LeprR deficiency (van de Wall et al. , 2008). Hence, there
must be other neuronal populations that mediate leptin’s effect on food intake and energy
expenditure, e.g. neurotensin expressing neurons in the LH and dopaminergic neurons
in the ventral tegmental area (VTA) (Domingos et al. , 2011; Leinninger et al. , 2011).
Another gene that is regulated by leptin induced STAT3 signaling is the suppressor of
cytokine signaling (SOCS)-3. Its transcription is also induced by the binding of STAT3 to
its promotor, but it acts as a negative regulator of JAK-STAT signaling by a competitive
binding to the phosphorylated tyrosine residues of JAK2 (Bjorbaek et al. , 1998; Endo et al.
, 1997; Howard et al. , 2004). Thus, haploinsufficiency for SOCS-3 or the deletion of SOCS-
3 in POMC neurons results in enhanced leptin sensitivity, whereas the overexpression
and constitutive activation of STAT3 leads to a constant increase in SOCS-3 expression
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and consequently to impaired leptin signaling (Ernst et al. , 2009; Howard et al. , 2004;
Kievit et al. , 2006; Munzberg et al. , 2004).
In contrast to its action in anorexigenic POMC neurons, leptin signaling in AgRP neu-
rons inhibits the transcription of AgRP mRNA but a lack of LepRs in AgRP neurons
does not induce any changes in body weight and other metabolic parameters (Mizuno &
Mobbs, 1999; Van De Wall et al. , 2008).
Leptin binding to its receptor is also able to induce other signaling cascades. Activated
JAK2 is also able to phosphorylate insulin receptor substrate (IRS) proteins and therefore
induce the PI3K pathway (Hill et al. , 2008; Metlakunta et al. , 2011; Xu et al. , 2005).
Besides changes on the transcriptional level, leptin is able to induce changes in the
electrophysiological activity of neurons via non-specific cation-channels (Cowley et al. ,
2001). However, this seems to be restricted to specific neuron populations, e.g. the POMC
expressing neurons, but also neurons in the VMH (Dhillon et al. , 2006).
Taken together, leptin signaling in the brain is mandatory for the maintenance of en-
ergy homeostasis, although the exact neuronal populations for leptin’s anorectic action
still need to be further defined.
1.6 Leptin Resistance
As mentioned before, leptin’s ability to reduce food intake and stimulate energy expen-
diture is heavily impaired in obese subjects (Enriori et al. , 2007). Although obese rodents
and humans display massively elevated leptin levels in the bloodstream, leptin is not
able to induce an intracellular signaling cascade and hence fails to prevent further intake
of calories or to induce energy expenditure (Heymsfield et al. , 1999). The molecular basis
for the development of leptin resistance is still under investigation, but one important
factor seems to be the negative regulator of leptin signaling, SOCS-3. Leptin induces
the expression of SOCS-3 as a negative feedback loop (Endo et al. , 1997; Naka et al. ,
1997). As demonstrated by Ernst and colleagues, constant activation of STAT3 in POMC
neurons leads to a massive increase in SOCS-3 mRNA levels, resulting in impaired lep-
tin signaling in the affected neurons (Ernst et al. , 2009). The deletion or knockdown of
SOCS-3 and haploinsufficiency results in lean mice, that are resistant to diet-induced obe-
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Figure 1.3: Leptin signaling pathway.
Upon leptin binding to LepRb, the associated JAK2 auto-phosphorylates itself and the LepRb at
three tyrosine residues. This phospho-tyrosines act as binding site for signal transducer and ac-
tivator of transcription STAT3, that is also phosphorylated by JAK2 (p-STAT3). p-STAT3 able to
dimerize, thereby the NLS gets exposed and the homo-dimers translocate to the nucleus. When
bound to its consensus sequence, p-STAT3 is able to induce the transcription of SOCS-3 to inhibit
further signaling of LepRb. Activated JAK2 is also able to phosphorylate the PI3K and thereby
activates the PI3K-pathway.
AKT, protein kinase B; IRS, insulin receptor substrate; JAK2, janus kinase 2; LepRb, leptin
receptor isoform b; NLS, nuclear localization signal; PDK1, phosphoinositide dependent ki-
nase 1; PI3K, phosphatidyl inositol 3 kinase; PiP2, phosphatidylinositol-(4,5)-bisphosphate; PiP3,
phosphatidylinositol-(3,4,5)-triphosphate, STAT3, signal transducer and activator of transcription
3; SOCS-3, suppressor of cytokine signaling 3.
sity (DIO) (Björnholm et al. , 2007; Howard et al. , 2004; Liu et al. , 2011). Due to the fact
that leptin exerts most of its functions in the brain, a neuron specific SOCS-3 knockout
already improves the effects of DIO and leads to enhanced leptin sensitivity (Mori et al.
, 2004). Therefore, it is possible that leptin itself is one of the main contributors to the
development of obesity and leptin resistance by its own negative feedback loop.
Another molecule involved in the development of leptin resistance is protein tyrosine
phosphatase (PTP)1B, a phosphatase that negatively regulates multiple signaling path-
ways that are using receptor tyrosine kinases (Haj et al. , 2002). PTP1B de-phosphorylates
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JAK2 and consequently shuts down further downstream signaling via STAT3. Similar to
SOCS-3, neuronal inactivation of PTP1B decreases adiposity and improves leptin sensi-
tivity in mice (Banno et al. , 2010; Bence et al. , 2006).
The endoplasmatic reticulum (ER) is the main source for newly synthesized proteins,
as the folding into the tertiary and quaternary structure is facilitated in this organelle. In
states of obesity, a lot of proteins are mis-folded in the ER, leading to an activation of ER
stress pathways in order to either re-fold these proteins or to convey them to proteasomal
degradation (Blond-Elguindi et al. , 1993; Chen et al. , 2002). The induction of the unfolded
protein response (UPR) activates several kinases as PERK and Ire1, leading to the tran-
scriptional activation of chaperones and the general inhibition of translation (Bernales
et al. , 2006). If these ER stress pathways are impaired, obesity and leptin resistance are
ameliorated (Ogimoto et al. , 2006; Ozcan et al. , 2009, 2004; Zhang et al. , 2008b).
Besides these cell intrinsic mechanisms, the obesity associated activation of immune
cells and inflammatory pathways also participate in the attenuation of leptin signaling.
Several pro-inflammatory cytokines, such as tumor necrosis factor (Tnf)α and multiple
interleukins, have been shown to negatively regulate leptin signaling (Arruda et al. , 2011;
De Taeye et al. , 2007; Denis et al. , 2010; Esposito et al. , 2003; Kern et al. , 2001). The
activated kinases c-jun n-terminal kinase (JNK) and inhibitor of nuclear factor kappa-B
kinase (IKK) seem to interfere with leptin’s ability to decrease food intake, as the global
deletion of JNK1 ameliorates obesity (Hirosumi et al. , 2002; Velloso et al. , 2008; Zhang
et al. , 2008b). But also nutrients like saturated free fatty acids (FFA) are able to induce
inflammatory signaling cascades via toll-like receptors (TLR)2 and 4 (Reyna et al. , 2008;
Shi et al. , 2006; Tsukumo et al. , 2007). Kleinridders and colleagues could demonstrate that
mice deficient for MyD88, an adaptor molecule used by all TLR isoforms, show improved
leptin sensitivity when exposed to high-fat diet (HFD) (Kleinridders et al. , 2009).
Although all these factors might contribute to the development of a systemic leptin
resistance observed in obese patients and rodents, nutrient derived FFAs are a key factor
in the initiation of diet-induced obesity associated inflammation (Cintra et al. , 2012).
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1.7 Insulin and Insulin Signaling
Beside leptin, insulin is the best characterized hormone in the control of energy home-
ostasis. Although it was discovered decades before leptin, insulin’s action was believed
to be limited to the periphery, where its effects were intensively studied. However, to-
wards the end of the seventies, studies indicated that insulin receptors are expressed and
that signaling is functional in the brain (Havrankova et al. , 1978a,b, 1979).
Insulin was discovered by Banting and Best as a pancreatic extract for the treatment of
diabetes (Banting et al. , 1922). It is produced by pancreatic β-cells in the Langerhans islets
as pre-proinsulin (Steiner et al. , 1967). Pre-proinsulin gets processed in two subsequent
steps in the ER into the bioactive insulin, as which it is stored in cytoplasmatic secretory
vesicles (Davidson et al. , 1988; Docherty & Hutton, 1983; Massaglia et al. , 1968). To exert
its functions in its target organs, insulin is secreted in a tightly controlled process. Upon
meal ingestion blood glucose levels rise, leading to a nonspecific import into the β-cells
via glucose transporter (GLUT)2. Glucose gets metabolized into ATP via glycolysis and
the citric acid-cycle, subsequently leading to the closure of ATP-dependent potassium
(KATP) channels (Ashcroft, 2005). The resulting increase in potassium ions in the cytosol
depolarizes the membrane potential and thereby activates voltage-gated calcium chan-
nels. This triggers the fusion of secretory insulin vesicles with the plasma membrane
(Ashcroft, 2006). Via the blood circulation, insulin is able to reach it target organs; mainly
the liver, muscle and adipose tissue, but also the CNS. In the muscle and in adipocytes,
insulin leads to the induction of an intracellular signaling cascade, enabling the translo-
cation of an insulin dependent glucose transporter (GLUT4) to the plasma membrane
and consequently to an uptake of glucose from the circulation, and further storage in
the form of glycogen or fat (Blüher et al. , 2002; Brüning et al. , 1998; Shepherd & Kahn,
1999). In adipocytes, insulin prevents lipolysis by the transcriptional inhibition of lipases
and simultaneously increases lipogenesis (Claycombe et al. , 1998; Jaworski et al. , 2007;
Kershaw et al. , 2006; Semenkovich et al. , 1989). The major effect of insulin in the liver is
to inhibit gluconeogenesis and glycogenolysis to prevent an additional rise in circulating
glucose (Cross et al. , 1995; Puigserver et al. , 2003).
The insulin receptor (IR) is a tetrameric receptor tyrosine kinase that consists of two
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α- and two β-subunits, both synthesized by a single gene with 22 exons by proteolytic
processing (Kasuga et al. , 1982; Ullrich et al. , 1985). It exists in two isoforms, IR-A and
IR-B, which are generated by alternative splicing of exon 11, from which IR-B is mainly
expressed in insulin target tissues (Benecke et al. , 1992; Moller et al. , 1989; Seino & Bell,
1989).
Upon binding of insulin to the extracellular α-chain of the receptor, the receptor un-
dergoes conformational changes and is thus able to auto-trans-phosphorylate itself at the
intracellular β-chains at various tyrosine residues (Kahn et al. , 1978). These phosphoryla-
tion sites then act as a docking platform for insulin receptor substrate (IRS) proteins that
can bind via their phosphotyrosine binding (PTB) domains and in turn become phos-
phorylated themselves (Eck et al. , 1996; Miralpeix et al. , 1992; White et al. , 1988). Ad-
ditionally, IRS proteins contain a pleckstrin homology (PH) domain, that interacts with
phospholipids and thereby targets IRS proteins to the plasma membrane (Burks et al. ,
1997, 1998; Jacobs et al. , 2001). Of the five known IRS isoforms, IRS 1 and 2 seem to be
the most important ones in the transmission of the insulin signaling cascade (Lavan et al.
, 1997a,b; Sun et al. , 1991, 1995).
Activated IRS proteins are able to induce several downstream signaling pathways,
but the best characterized in respect to energy homeostasis is the phosphoinositide-3-
kinase (PI3K) pathway. The PI3K can bind to the phosphorylated tyrosine residues of
the IRS proteins with its rous sarcoma virus (Src)-homology (SH) 2 domain (Lavan et al.
, 1992), leading to a de-inhibition of the regulatory subunit p85 and thereby an activa-
tion of the catalytic subunit p110 (Lavan & Lienhard, 1993; Myers et al. , 1992, 1994a).
The activated PI3K is able convert phosphaditylinositol-(3,4)-bisphosphate (PiP2) into
phosphaditylinositol-(3,4,5)-triphosphate (PiP3), which acts as a second messenger at the
plasma membrane (Myers et al. , 1993; Skolnik et al. , 1991; Whitman et al. , 1988). This is
counteracted by the negative regulator of the PI3K pathway, the phosphatase and tensin
homolog (PTEN). PTEN de-phosphorylates PiP3 back to PiP2, thereby negatively regu-
lating the signaling pathway (Maehama & Dixon, 1998). PiP3 recruits of the phosphadi-
tyinositol dependent kinase 1 (PDK1) to the plasma membrane, which induces further
downstream signaling, consequently leading to the phosphorylation and activation of
15
1 Introduction
the proteinkinase B (AKT). AKT is then able to phosphorylate, among others, the tran-
scription factor forkhead box protein O1 (FOXO1) (Alessi et al. , 1997a,b; Anderson et al. ,
1998; Casamayor et al. , 1999; Currie et al. , 1999; Pullen et al. , 1998). FOXO1 is a transcrip-
tion factor that is exported from the nucleus upon phosphorylation, gets ubiquitylated
in the cytoplasm and finally degraded by the 26S proteasome (Huang & Tindall, 2007;
Lin et al. , 1997; Ogg et al. , 1997). In POMC neurons, FOXO1 and STAT3 have overlap-
ping binding sites at the POMC promotor where FOXO1 inhibits, and STAT3 activates,
transcription of the POMC gene. Therefore both insulin and leptin signaling in POMC
neurons is necessary to fully activate transcription of POMC (Belgardt et al. , 2008). In
AgRP neurons FOXO1 and STAT3 have opposite effects. FOXO1 acts as activator and
STAT3 as suppressor of the transcription of AgRP (Kitamura et al. , 2006).
The PI3K pathway serves as a convergence point of both leptin and insulin signaling.
Therefore it is difficult to curtail the effects of the PI3K pathway to either leptin or insulin.
Current results indicate that different isoforms of the PI3K might be responsible for either
leptin’s or insulin’s effect on the downstream signaling (Hill et al. , 2008, 2009), whereas
for certain functions, especially in the brain, both are necessary to fully induce the PI3K
pathway (Koch et al. , 2010).
Beside the PI3K pathway, insulin is also able to activate the MAPK pathway. Phospho-
tyrosine residues on IRS proteins act as a binding platform for the growth factor receptor-
bound protein (Grb), that thereby activates the MAPK pathway (Myers et al. , 1994b;
Skolnik et al. , 1993). In contrast to the PI3K pathway, the MAPK pathway is considered
to be more important in cell survival, proliferation and growth (figure 1.4) (Skolnik et al.
, 1993; Wada et al. , 1998).
The importance of insulin signaling in the control of energy homeostasis is highlighted
by multiple publications over the last decades. The specific deletion of IRs in the skeletal
muscles reflects the symptoms of T2DM, showing that most of the glucose uptake is in-
sulin dependent (Brüning et al. , 1998). A similar phenotype was reported in mice lacking
IRs in hepatocytes. These mice displayed severe hyperglycemia and systematic insulin
resistance (Michael et al. , 2000). On the contrary, the adipose tissue specific knockout of
the IR is protected against the development of obesity and consequently against T2DM,
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showing that insulin is a critical factor in the differentiation and expansion of adipocytes
(Blüher et al. , 2002; Kershaw et al. , 2006).
Besides these effects in peripheral tissues, insulin action in the brain is of great impor-
tance in the control of energy homeostasis and reproduction. The neuron specific insulin
receptor knockout (NIRKO) mouse is slightly obese and shows hypothalamic hypogo-
nadism (Brüning et al. , 2000). Furthermore, insulin signaling in the brain has critical
functions in the control of adipogenesis (Koch et al. , 2008; Scherer et al. , 2011). Fur-
ther experiments allowed a deeper look into insulin’s action in the brain. By knocking
out the IR in hypothalamic neuron populations, Könner and colleagues could show that
insulin signaling in AgRP, but not in POMC neurons is necessary to suppress hepatic glu-
cose production (Könner et al. , 2007). In POMC neurons, insulin signaling is needed to
fully activate the transcription of POMC, shown by the deletion of PDK1 (Belgardt et al.
, 2008). On the other hand, hyperactivation of the insulin pathway by a deletion of the
phosphatase PTEN also results in overweight mice, leading to the hypothesis that insulin
is able to silence POMC neurons via KATP channels (Plum et al. , 2006).
1.8 Insulin Resistance
The association of obesity with T2DM has been recognized over the last decades and
resistance to the hormone insulin is one of the hallmarks in the progression of T2DM
(Brüning et al. , 1997; Kahn, 1994a; Reaven, 1995). In initial and mild states of insulin
resistance, the pancreatic β-cells are able to compensate the increased demand for in-
sulin by an increased production and secretion of insulin. But insulin resistance is, if not
treated, a progressing disorder leading to further demands of insulin to maintain eug-
lycemia (Martin et al. , 1992). This results in hyperplasia and increased secretion activity
of the insulin producing β-cells, that eventually collapse (Parsons et al. , 1992; Pipeleers,
1992). Subsequently, insulin fails to suppress hepatic glucose production and to induce
glucose uptake into muscle tissue and adipocytes, hence resulting in severely elevated
blood glucose levels and finally in T2DM (Kahn, 1994b). Furthermore, T2DM predis-
poses for associated diseases such as diabetic retinopathy, hypertension, angiopathy and
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Figure 1.4: Insulin signaling pathway.
Binding of insulin leads to a conformational change of the IR, ending in activation of the intrin-
sic kinase ability. After auto-phosphorylation of the IR, IRS proteins bind to the phosphorylated
residues by their SH2 domains, and are themselves phosphorylated by the IR. Grb binds via its
SH2 domain, eliciting activation of the Ras-Raf-MAPK signalling pathway, which mediates some
of insulin’s effects on growth. Phosphorylation of IRS proteins allows binding of p85, the regula-
tory subunit of the PI3K complex. This de-inhibits p110, the catalytic subunit of PI3K, which sub-
sequently phosphorylates the membrane lipid PiP2 to generate PiP3. PiP3 accumulation in turn
will recruit and allow binding of both PDK1 and AKT via their PH domains. After co-localisation
induced by PiP3 binding, PDK1 phosphorylates and thereby activates AKT, which mediates most
of insulin’s effect on glucose and glycogen metabolism, as well as activating protein translation
and gene transcription.
AKT, protein kinase B; FOXO1, forkhead-O transcription factor 1; Grb, growth factor recep-
tor bound; IR, insulin receptor; IRS, insulin receptor substrate; MAPK, mitogen-activated pro-
tein kinase; PDK1, phosphoinositide dependent kinase 1; PI3K, phosphoinositide 3-kinase; PiP2,
phosphatidylinositol-(4,5)-bisphosphate; PiP3, phosphatidylinositol-(3,4,5)-triphosphate, STAT3,
signal transducer and activator of transcription 3; Ras, Rat sarcoma protein; Sos, son of sevenless
neuropathy (Gastaldelli et al. , 2000; Reaven, 1995; Semenkovich, 2006; van Leiden et al. ,
2002).
The full clinical manifestation of insulin resistance occurs only in rare monogenic dis-
orders, such as Donohue or Rabson-Mendenhall syndrome. In these syndromes insulin
resistance is caused by mutations or polymorphisms in insulin signaling molecules, such
as AKT, PI3K or IRS proteins that impair the signaling downstream of the IR (Semple et al.
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, 2011). But in the vast majority of patients, the exact molecular mechanisms underlying
insulin resistance are not fully understood.
Obesity is associated with a chronic low-grade inflammatory state, indicated by ele-
vated levels of pro-inflammatory cytokines such as Tnf-α and IL-6 in the blood circulation
and in the white adipose tissue (WAT) (Hotamisligil et al. , 1993; Wellen & Hotamisligil,
2005). These inflammatory cytokines induce intracellular stress-signaling cascades that
lead to the activation of effector kinases such as JNK and IKK, that are able to inhibit
insulin signaling by an inhibitory phosphorylation at serine residues of IRS proteins (Cai
et al. , 2005; Hirosumi et al. , 2002; Hotamisligil et al. , 1996; Shoelson et al. , 2003). Ser-
ine phosphorylation of the IRS protein inhibits downstream signaling as it prevents the
binding of IRS proteins to the IR by their PTB domain (Aguirre et al. , 2000, 2002; Paz
et al. , 1997). Consequently, the inhibition of inflammation or the deletion of the effector
kinases improves insulin sensitivity (Belgardt et al. , 2010; Hirosumi et al. , 2002; Sabio
et al. , 2008, 2009, 2010). But not only inflammatory cytokines are able to activate stress-
signaling cascades. It has been shown that ER stress, beside impairing leptin’s action,
is also able to induce insulin resistance via the unfolded-protein response (Bailly-Maitre
et al. , 2010; Ozcan et al. , 2009, 2004; Zhang et al. , 2008b). Futhermore, FFAs, that are
elevated in the circulation upon HFD-feeding, have been shown to induce intracellular
JNK signaling via toll-like receptors (TLR) 2 and 4. Hence, deletion of TLR4 improves
insulin sensitivity in muscle tissue of diet-induced obese mice (Davis et al. , 2009; Radin
et al. , 2008; Shi et al. , 2006). But FFAs are also able to activate via diacylglycerols pro-
tein kinase C (PKC) isoforms that have been shown to interfere with insulin signaling by
serine phosphorylation of IRS proteins (Bandyopadhyay et al. , 2005; Benoit et al. , 2009).
Another mechanism of FFA-induced insulin resistance is the activation of protein phos-
phatase 2A (PP2A), that is able to de-phosphorylate AKT (Galbo et al. , 2011). Also the
aforementioned unspecific phosphatase PTP1B is activated by FFAs and inflammation
and impairs insulin signaling by de-phosphorylation of IRS proteins (Galbo et al. , 2011).
Consistently, PTP1B knockout mice are protected against diet-induced insulin resistance
(Elchebly et al. , 1999).
Beside FFA, ceramides, a class of sphingolipids, are also implicated in the develop-
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ment of insulin resistance, possibly again by activating JNK and IKK (Chavez & Sum-
mers, 2012).
1.9 The Ventromedial Hypothalamus and Steroidogenic factor 1
The Ventromedial Hypothalamus (VMH) was for a long time considered to be the most
important satiety center in the brain. By either lesion experiments, leading to increased
food intake and obesity, or by electrical stimulation, leading to anorexia, the importance
of this nucleus in the regulation of energy homeostasis was demonstrated (Aravich &
Sclafani, 1983; Boyle, P. C. & Keesey, 1975; Hetherington & Ranson, 1940; Leibowitz et al.
, 1981; Olney & Sharpe, 1969; Stevenson et al. , 1950). Researchers used the model of hy-
pothalamic obesity for their investigations, which resulted from a lesioned VMH (Anand
& Brobeck, 1951; Brobeck, 1946).
Upon the discovery of the melanocortin system, the VMH was neglected by most
researchers. Imprecise techniques and a lack of knowledge about the neurons in the ARC
were considered to be the reason of the phenotype in hypothalamic obesity (probably
the ARC was also lesioned in addition to the VMH). The VMH was then believed to
be a possible projection target for POMC or AgRP neurons in the regulatory metabolic
neurocircuitry that further process the melanocortin derived neuroendocrine signals (Fu
& van den Pol, 2008).
This view changed when the orphan receptor Steroidogenic Factor 1 (SF-1) was discov-
ered to be expressed in the VMH (Ikeda et al. , 1994). Initial experiments revealed a lethal
phenotype in mice with a whole body knockout due to a failure in the development of the
adrenal glands (Sadovsky et al. , 1995). But when these mice were rescued by a transplan-
tation of adrenal glands, they developed severe obesity due to an absent VMH (Majdic
et al. , 2002). These results established SF-1 as a marker for the VMH.
In initial studies by Dhillon and colleagues in 2006, a transgenic mouse with the Cre
recombinase under the control of the SF-1 promotor was created. They could show that
the Cre is expressed predominantly in the VMH with minor expression in the adrenal
gland, testis and pituitary gland. Using this transgenic mouse to delete the leptin re-
ceptor specifically in VMH neurons revealed a direct role for leptin to regulate the elec-
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trophysiological activity of these neurons. Interestingly, the authors were able to show
that the effect of leptin signaling in the VMH is independent of leptin action on POMC
neurons. Whereas the single deletion of LepRs on POMC and SF-1 neurons led to only
modest obesity, the deletion of LepRs on both neuron populations caused severe obesity,
reflecting the sum of the weight gain observed in the individual deletion of the receptor
in the respective neurons (Bingham et al. , 2008; Dhillon et al. , 2006).
Furthermore, the same group could show that glutamatergic output of SF-1 express-
ing neurons was mandatory for normal body weight regulation. Mice lacking the gluta-
mate transporter VGLUT2 in SF-1 neurons, leading to an impaired glutamate release, also
showed an increase in body weight and modest hyperphagia (Tong et al. , 2007b). These
findings correspond with the results of Sternson and colleagues, who were able to show,
by a combination of uncaging experiments in the VMH together with electrophysiologi-
cal recordings of ARC POMC and AgRP neurons, that unidentified VMH neurons build
excitatory hotspots on POMC neurons (Sternson et al. , 2005). This further highlights the
role of SF-1 expressing neurons in the homeostatic mechanism of melanocortin regulated
body weight control.
1.10 Counter-regulatory Response to Hypoglycemia
Apart from being involved in the regulation of energy homeostasis, VMH neurons also
play a role in the detection and counter-regulation of hypoglycemia, one of the major
limitations in the treatment of type 1 and 2 diabetes patients with insulin (Borg et al. ,
1994; Cryer et al. , 2003).
Due to the fact that the brain uses glucose as the major (and almost exclusive) fuel, it is
very sensitive to a drastic fall of blood glucose concentrations (Cryer et al. , 2003). There-
fore, powerful neuroendocrine and autonomic counter-regulatory mechanisms protect
the brain against severe hypoglycemia (Cryer, 2008). This is achieved by the release of
epinephrine, norepinephrine, corticosterone and glucagon into the circulation, leading to
an increase of hepatic glucose production and an inhibition of peripheral glucose uptake
(figure 1.5) (Cryer et al. , 2003; Dagogo-Jack et al. , 1993; Heller & Cryer, 1991). But the
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mechanism how the brain senses hypoglycemia and how the appropriate release of the
aforementioned hormones is facilitated is still under investigation.
The first evidence pointing towards the involvement of the VMH in the counter-
regulatory response to hypoglycemia (CRR) came from VMH-lesioned rats that showed
an impaired CRR (Borg et al. , 1994). This was verified by either glucose infusion into the
VMH or the induction of local glucopenia in the VMH (Borg et al. , 1997, 1999, 1995). Fur-
thermore, both glucose excited (GE) but also glucose inhibited (GI) neurons were found
within the VMH (Song et al. , 2001). Thus, glucose sensing in the VMH has a pivotal role
in the induction of CRR (Kang et al. , 2006; Levin et al. , 2004). Several factors are involved
in VMH’s glucose sensing and hence the induction of CRR. AMP-activated protein ki-
nase (AMPK) plays a central role since activation of AMPK with 5-aminoimidazole-4-
carboxamide (AICAR) amplifies the hormonal CRR (McCrimmon et al. , 2006). Similarly,
the KATP channels, that are key mediators of glucose stimulated insulin release from pan-
creatic β-cells, are implicated in the mechanism of glucose sensing. Mice deficient for the
regulatory subunit of KATP channels, Kir6.2, show an impaired CRR (Miki et al. , 2001).
But also nitric oxide (NO) is necessary for glucose sensing and the induction of CRR.
AMPK is able to phosphorylate and thereby activate the neuronal nitric oxide synthase
(nNOS), leading to the production of NO that can signal via soluble guanylyl cyclase
(sGC). Blockade of any of these steps leads to a loss of glucose sensing ability (Canabal
et al. , 2007; Murphy et al. , 2009).
Insights into insulin’s role in the induction of CRR is derived from experiments in
neuronal insulin receptor knockout (NIRKO) mice. These mice displayed an impaired
CRR when exposed to insulin induced hypoglycemia, caused by an impaired glucagon
release from α-cells in the pancreas (Fisher et al. , 2005).
Further evidence for the involvement of VMH and especially SF-1 neurons was pro-
vided by Tong and colleagues who could show that glutamate release from SF-1 neurons
is necessary for the induction of the CRR. Both insulin induced hypoglycemia and fast-
ing, but also local glycopenia mediated CRRs were blunted in mice lacking VGLUT2 in
SF-1 neurons, again caused by an impaired release of glucagon and epinephrine into the
circulation (Tong et al. , 2007a).
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Finally it could been shown that a lack of IRs in the brain leads to a reduced expres-
sion of the glucose transporter GLUT4 in the brain, particularly in the VMH, leading
to a defect in glucose sensing of those neurons. This resulted again in reduced levels
of epinephrine secreted from the adrenal gland and thus to an impaired CRR (Diggs-
Andrews et al. , 2010).
Although both insulin signaling and VMH neurons are key factors in the CRR, it is
still unclear whether SF-1 neurons represent the central glucose sensing neurons in the
VMH, mediating insulin’s effect in the counter-regulation against hypoglycemia.
Decreased blood glucose
VMH
Sympathetic and para-sympathetic
nervous system
Adrenal gland Pancreas
Epinephrine
Norepinephrine
Corticosterone
Glucagon
Hepatic glucose
production
Liver
Figure 1.5: Schematic overview of the counter-regulatory response to hypoglycemia.
The brain, especially the ventromedial hypothalamus (VMH), senses decreasing blood glucose
concentrations and triggers the release of epinephrine, norepinephrine and corticosterone from
the adrenal glands and the secretion of glucagon from pancreatic α-cells via the sympathetic and
para-sympathetic nervous system These hormones increase the hepatic glucose production to
counter-regulate the hypoglycemia.
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1.11 Objectives
The role of the VMH as important hypothalamic nucleus in the control of energy home-
ostasis is well established. Likewise, insulin’s action in distinct neuronal populations
as a regulator of peripheral glucose production has been intensively studied, e.g. in
POMC and AgRP neurons (Könner et al. , 2007), further refining the results of Brüning
and colleagues (Brüning et al. , 2000). Additionally, the NIRKO mouse used in the latter
publication has been further studied with respect to the counter-regulatory response to
hypoglycemia (CRR), establishing insulin as key factor in the induction of the CRR. The
identification of steroidogenic factor 1 (SF-1) as a marker for the VMH and the subse-
quent creation of a mouse line, using the SF-1 promotor to drive the expression of the
Cre recombinase, allowed further insight into the role of leptin signaling in the VMH in
control of energy homeostasis (Dhillon et al. , 2006; Zhang et al. , 2008a), but also into the
role of SF-1 expressing neurons in the induction of CRR (Tong et al. , 2007a). Hence, the
SF-1 Cre mouse line is a new tool that enables a detailed investigation of insulin signaling
in the VMH.
Due to the importance of the VMH in the regulation of body weight maintenance, as
shown in lesion experiments, SF-1 neurons might be a target for insulin in the CNS. Thus,
the aim of this study was to create mice that specifically lack the insulin receptor (IR) in
SF-1 neurons (SF-1∆IR) and to investigate the effect of lacking insulin signaling on SF-1
neurons in terms of energy homeostasis and glucose metabolism. To over-activate the in-
sulin signaling pathway, mice were generated lacking the phosphatase PTEN (SF-1∆PTEN ;
by Dr. Bengt F. Belgardt) and both PTEN and IR simultaneously (SF-1∆IR:PTEN). More-
over, the role of insulin signaling in SF-1 neurons in the CRR was analyzed by exposing
the mice to hypoglycemic-hyperinsulinemic clamp studies.
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2.1 Mouse experiments
General mouse handling was performed according to Silver (1995)
2.1.1 Animal care
Care of all animals was within institutional animal care committee guidelines. All an-
imal procedures were conducted in compliance with protocols and approved by local
government authorities (Bezirksregierung Köln, Cologne, Germany) and were in accor-
dance with NIH guidelines. Animals were housed in groups of 3 - 5 mice per cage at
an ambient temperature of 22 - 24◦C and kept at a 12-hour light / 12-hour dark cycle.
Animals were either fed normal chow diet (NCD; Teklad Global Rodent 2018; Harlan)
containing 53.5% carbohydrates, 18.5% protein, and 5.5% fat (12% of calories from fat) or
a high-fat diet (HFD; C1057; Altromin) containing 32.7% carbohydrates, 20% protein, and
35.5% fat (55.2% of calories from fat). Animals had ad libitum access to water and food
at all times. Food was only withdrawn if required for an experiment. Body weight was
measured once a week; body length (naso-anal length) was measured after sacrificing.
Mice were sacrificed by lethal CO2 anesthesia.
2.1.2 Experimental mice
SF-1 Cretg/wt mice (Dhillon et al. , 2006) were mated with IR f l/ f l mice (Brüning et al.
, 1998) to generate SF-1 Cretg/wt;IR f l/ f l animals (SF-1∆IR) with IR f l/ f l animals as con-
trol. SF-1∆IR were further bred to PTEN f l/ f l mice (Suzuki et al. , 2001) to generate SF-
1 Cretg/wt;IR f l/ f l :PTEN f l/ f l , that lack both IR and PTEN in SF-1 expressing cells (SF-
1∆IR:∆PTEN) with the respective SF-1 Cre negative animals as control. For immunohis-
tochemistry (IHC) experiments and electrophysiological recordings SF-1∆IR were mated
with either Z/eG or RosaArte1 mice (SF-1GFP:∆IR and SF-1lacZ:∆IR) (Novak et al. , 2000;
Seibler et al. , 2003). As controls, SF-1 Cretg/wt animals were also bred to Z/eG and
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RosaArte1 mice to generate SF-1GFP and SF-1lacZ. For electrophysiology experiments in
POMC neurons, transgenic mice with GFP under control of the Pomc promotor (POMCGFP)
(Cowley et al. , 2001) were mated with SF-1∆IR to generate POMCGFP:SF-1∆IR, that express
GFP in POMC neurons but lack the IR in SF-1 neurons. SF-1 Cre negative animals served
as controls(POMCGFP;IR f l/ f l), further named POMCGFP.
2.1.3 Food intake and indirect calorimetry
Daily food intake was calculated as the average intake of NCD or HFD from custom made
food racks within the time stated. Mice were acclimated to the food intake settings for
at least five days. Weight of the racks was determined daily. Calorimetry measurements
were performed in a PhenoMaster System (TSE systems, Bad Homburg, Germany and
CLAMS, Oximax Windows 4.00, Columbus Instruments, Columbus, OH, USA), which
allows measurement of metabolic performance and activity-monitoring by an infrared
light-beam frame (TSE systems). Mice were placed at room temperature (22 ◦C–24 ◦C) in
7.1-l chambers of the PhenoMaster open circuit calorimetry. Mice were allowed to adapt
to the chambers for at least 48 hours. Food and water were provided ad libitum in the
appropriate devices and measured by the build-in automated instruments. Locomotor
activity and parameters of indirect calorimetry were measured for at least the following
48 hr. Presented data are average values obtained in these recordings.
2.1.4 Blood collection and determination of glucose levels
Tail bleeding was performed as described before (Silver, 1995). Blood glucose values were
determined from whole venous blood using an automatic glucose monitor (GlucoMen;
A. Menarini Diagnostics, Florence, Italy). Venous blood samples were stored on ice for
15 minutes and subsequently centrifuged at 13.000 rpm for 20 minutes. Resulting serum
was stored at -20◦C. For collection of plasma, EDTA (1.6 mg/1ml serum) was added to
prevent clotting. Determination of blood glucose levels and collection of blood samples
from control and various conditional knockout mice were performed side-by-side in the
morning to avoid intra-group deviations due to circadian variations.
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2.1.5 Analysis of body composition
Body fat content was measured in vivo by nuclear magnetic resonance using a minispec
mq7.5 (Bruker Optik, Ettlingen, Germany). Radiofrequency pulse sequences are trans-
mitted into mouse tissue, which are retransmitted by hydrogen atoms in the tissue, the
signals of which are detected by the minispec. Amplitude and duration of these signals
are related to properties of the material.
2.1.6 Glucose and insulin tolerance test
For glucose tolerance tests (GTT), mice were fasted overnight for 16h. After determina-
tion of fasted blood glucose levels, each animal received an intraperitoneal injection of
20% glucose solution (10ml/kg body weight). Blood glucose was determined 15, 30, 60
and 120 min after injection. For insulin tolerance tests (ITT), each random fed animal re-
ceived an intraperitoneal injection of 0.75U/ml insulin-solution (0,75U/kg body weight)
after determination of random fed blood glucose concentration. Blood glucose was de-
termined 15, 30, 60 min after injection, and blood glucose concentrations were calculated
relative to starting blood glucose levels.
2.1.7 Leptin sensitivity
Intracerebroventricular cannulas were implanted as previously described (Brown et al.
, 2006), except that the lateral ventricle was targeted using coordinates located using a
brain atlas (coordinates were bregma 1.0 mm lateral, 0.2 mm caudal and 2.0 mm ventral).
After one week recovery and an overnight fast, mice were injected with 2 µl artificial
cerebrospinal fluid (aCSF). Food intake was measured 4 and 8 h later. After a 7 d break,
5 µg mouse leptin (NHPP) in 2 µl was injected and food intake was measured 4 and 8
h later. On the basis of the notion that SF-1∆IR mice are protected from HFD-induced
obesity, data were analyzed by unpaired, one-tailed Student’s t-test.
2.1.8 Fertility assesment
IR f l/ f l (control) and SF-1∆IR males were mated with SF-1∆IR and control females, re-
spectively. Litter frequency and mean litter size were analyzed for at least four litters.
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Additionally, testes and ovaries were examined for morphological abnormalities. There-
fore, testes and ovaries of 20 week old animals were dissected, fixed overnight in 4%
formaldehyde and then embedded for paraffin sections. Subsequently, 7µm thick sec-
tions were deparaffinized and stained using haematoxylin and eosin (H&E) for general
histology. Images were taken with a Leica DM 1000 LED (Leica Microsystems, Wetzlar,
Germany).
2.1.9 Hypoglycemic Clamp studies
Catheter implantation
At the age of 12 weeks, female and male mice were anesthetized by i.p. injection of
avertin (240 mg/kg) and adequacy of the anesthesia was ensured by the loss of pedal
reflexes. A micro-renathane catheter (MRE 025; Braintree Scientific Inc.) was inserted into
the right internal jugular vein, advanced to the level of the superior vena cava, and secured
in the proximal part of the vein with 4-0 silk; the distal part of the vein was occluded
with 4-0 silk. After irrigation with physiological saline solution, the catheter was filled
with heparin solution and sealed at the distal end. The catheter was subcutaneously
tunneled, thereby forming a subcutaneous loop, and exteriorized at the back of the neck.
Cutaneous incisions were closed with a 4-0 silk suture and the free end of the catheter
was attached to the suture in the neck as to permit the retrieval of the catheter on the day
of the experiment. Mice were intraperitoneally injected with 1 ml of saline containing 15
µg/g body weight of Tramal and placed on a heating pad in order to facilitate recovery.
Hypoglycemic-hyperinsulinemic Clamp experiment
After 7 days of recovery, only mice that had regained 90% of their preoperative weight
were studied. After a 5-h fast, awake mice were placed in a tail-restraint apparatus, and
after an adjustment period, a 200 µl blood sample was collected from the tail tip. Sep-
arated plasma was stored for basal metabolite and hormone determinations, while ery-
throcytes were resuspended in saline and re-infused to avoid volume depletion. After
basal sampling, regular human insulin (Novo Nordisk, Bagsvaerd, Denmark) diluted in
saline with 0.1% BSA (Sigma) was infused (200 mU*kg−1 bolus and 20 mU*kg−1 *min−1)
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at time zero. Blood samples (∼ 2.2 µl) were drawn at 10 min intervals to measure blood
glucose (B-Glucose Analyzer; Hemocue). Extreme care was taken with the glucose infu-
sion (20% glucose; DeltaSelect) to gradually lower glycemia and match groups for levels
of hypoglycemia (∼ 50 mg*dl−1). No seizure activity was noted. A 200 µl blood sample
was drawn at the end of the 120 min hypoglycemic clamp for metabolite and hormone
assays.
2.2 Molecular biology
Standard methods in molecular biology were performed according to the protocols in
Sambrook & Russell (2001), if not mentioned afterwards.
2.2.1 Isolation of genomic DNA
Mouse tail biopsies were incubated overnight in lysis buffer (100mM Tris pH 8.5, 5mM
EDTA, 0.2% (w/v) SDS, 0.2M NaCl, 500mg/ml Proteinase K) in a thermoshaker (Eppen-
dorf, Hamburg, Germany) at 55◦C. After removal of tissue debris, DNA was precipitated
by adding an equivalent volume of 2-Propanol (100%) and centrifuged at 13000 rpm for
15 minutes. After washing with 70% (v/v) ethanol and subsequent centrifugation, the
DNA pellet was dried and redissolved in TE buffer
2.2.2 Quantification of nucleic acids
DNA and RNA concentrations were quantified by measuring the sample absorption at
260 nm and 280 nm with a NanoDrop ND-1000 UV-Vis spectrophotomoter (Peqlab, Er-
langen, Germany). An optical density of 1 corresponds to approximately 50 µg/ml of
double stranded DNA and to 38 µg/ml of RNA. A ratio greater than 2 of absorptions at
260 nm (DNA/RNA) divided by the absorption at 280 nm (protein) was used as an index
of purity of DNA/RNA.
2.2.3 Polymerase chain reaction (PCR)
PCR was used to detect loxP flanked exons and various transgenes with primers de-
scribed in table 2.1. Reactions were performed in a Thermocycler iCycler PCR machine
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(BioRad, München, Germany) or in a Peltier Therman Cycler PTC-200 (MJ Research,
Waltham, USA). All amplifications were performed in a total reaction volume of 25 µl
containing a minimum of 50ng template DNA, 25pmol of each primer, 25µM dNTP mix,
polymerase buffer and 1 U of polymerase. Standard PCR programs started with 5 min-
utes (min) of denaturation at 95◦C, followed by 35 cycles consisting of denaturation at
95◦C for 45 seconds (sec), annealing at oligonucleotide-specific temperatures for 30 sec
and elongation at 72◦C for 30 sec, and a final elongation step at 72◦C for 5 min.
Table 2.1: PCR primers
Primer Sequence Annealing site / function Orientation
SF-1 Cre1 GGTCAGCCTAATTAGCTCTGT Ghrelin control sense
SF-1 Cre2 GATCTCCAGCTCCTCCTCTGTC Ghrelin control antisense
SF-1 Cre3 TGCGAACCTCATCACTCGTTGCAT Sf-1 promotor sense
SF-1 Cre4 CTGAGCTGCAGCGCAGGGACAT Cre antisense
IR-5’ GATGTGCACCCCATGTCTG Insr floxed exon sense
IR-3’ CTGAATAGCTGAGACCACAG Insr floxed exon antisense
IR-∆ GGGTAGGAAACAGGATGG Insr deletion sense
PTEN-5’ CTCCTCTACTCCATTCTTCCC Pten floxed exon sense
PTEN-3’ ACTCCCACCAATGAACAAAC Pten floxed exon antisense
LacZ1 AAAGTCGCTCTGAGTTGTTATC endogenous Rosa26 locus sense
LacZ2 GATATGAAGTACTGGGCTCTT endogenous Rosa26 locus antisense
LacZ3 GACAAACCACAACTAGAATGC transgenic lacZ allele antisense
Z/eG1 CAGGAACTCCAGCAGGACCATG Z/eG transgene sense
Z/eG2 CTGGTCGAGCTGGACGGCGACG Z/eG transgene antisense
POMC-GFP1 TGGCTCAATGTCCTTCCTGG Pomc promotor sense
POMC-GFP2 CACATAAGCTGCATCGTTAAG enogenous Pomc antisense
POMC-GFP3 CAGGAACTCCAGCAGGACCATG GFP antisense
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2.2.4 RNA extraction, RT-PCR and quantitative real-time PCR
Tissue samples were homogenized in Trifast (Peqlab, Erlangen, Germany) using an Ul-
tra Turrax homogenizer (IKA, Staufen, Germany). Subsequent purification of total RNA
was conducted according to the Trifast protocol by Peqlab. When exon-spanning probes
were not available to quantify RNA expression of target genes, on-column DNA diges-
tion was performed (RNAse-free DNAse, Qiagen, Hilden, Germany). 200ng RNA was
reverse-transcribed into cDNA using the Eurogentec RT KIT (Eurogentec, Belgium). For
quantitative real-time PCR, 100ng cDNA was amplified using Taqman Universal PCR-
mastermix, NO AmpERASE UNG with Taqman assay on demand kits (Applied Biosys-
tems, Foster City, USA) as shown in table 2.2. Relative expression of genes was adjusted
for total RNA content by glucuronidase (GUSB) and hypoxyanthine guanine phospho-
riboysl transferase (HPRT) 1 RNA. Real-time PCR analysis was performed on an ABI-
PRISM 7700 Sequence detector (Applied Biosystems, Foster City, USA). Assays were lin-
ear over 4 orders of magnitude.
Table 2.2: Real-time PCR probes
Gene Catalogue Nr. Gene Catalogue Nr.
Agrp Mm00435874_ml Bdnf Mm01334042_m1
Cart Mm00489086_m1 Fshb Mm00433361_m1
Gh Mm01258409_g1 Gusb Mm00446953_m1
Hprt Mm03024075_m1 Lh Mm00656868_g1
Npy Mm00445771_m1 Pomc Mm00435874_m1
Sf-1 Mm00446826_m1 Tshb Mm03990915_g1
2.3 Cell biology
2.3.1 Histological analysis and immunohistochemistry
SF-1 Cre mice were mated with RosaArte1 mice or Z/EG mice to generate SF-1lacZ and
SF-1GFP mice which served as controls for the immunohistochemistry studies
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(Novak et al. , 2000; Seibler et al. , 2003). SF-1∆IR mice were mated with RosaArte1 mice to
generate SF-1∆IR:lacZ mice which lack IR in SF-1 expressing cells but express lacZ in these
cells.
Mice were anesthetized and transcardially perfused with physiologic saline solution
followed by 4% paraformaldehyde (PFA) in 0.1 M phosphate buffered saline (PBS; pH
7.4). The brains were dissected, post- fixed in 4% PFA at 4◦C, transferred to 20% sucrose
for 6 h and frozen in tissue freezing medium. Then, 25 µm thick free-floating coronal
sections were cut through the ARC using a freezing microtome (Leica, Germany). The
sections were collected in PBS/azide (pH 7.4) and washed extensively to remove cry-
oprotectant. Subsequently, the sections were treated with 0.3% H2O2 in PBS for 20 min
to quench endogenous peroxidase activity. Following pretreatments, the sections were
processed using the Renaissance R© TSATM Fluorescence Systems Tyramide Signal Am-
plification Kit (PerkinElmerTM) according to manufacturer’s guidelines (primary anti-
body: rabbit anti-lacZ, #55976; Cappel; secondary antibody: goat anti-rabbit peroxidase
labeled, Vector Laboratories).
For visualization of GFP expression after Cre-recombination, SF-1GFP mice were anes-
thetized and transcardially perfused with physiologic saline solution followed by 4%
paraformaldehyde. Brains were dissected and post-fixed in 4% PFA at 4◦C, transferred
to 20% sucrose for 6 h and frozen in tissue freezing medium. Then, 25 µm thick free-
floating coronal sections were cut through the mediobasal hypothalamus using a freez-
ing microtome (Leica, Gemrany). The sections were washed, pretreated with 0.3% H2O2,
blocked with PBT/azide containing 3% donkey serum, and incubated overnight with
primary antibody (anti-GFP rabbit serum, 1:10.000 in blocking solution; A6455 from In-
vitrogen/Molecular Probes). Incubation with secondary antibody (anti-rabbit IgG biotin,
1:500; 711-065-152 from Jackson ImmunoResearch) was followed by an additional incuba-
tion with the VECTASTAIN Elite ABC kit (Vector Laboratories) for 1 h and visualization
with 0.4% DAB/0.01% H2O2. Afterwards the sections were mounted onto gelatin-coated
slides and covered with glycerin.
To determine the efficiency of IR deletion, SF-1lacZ control and SF-1∆IR:lacZ KO reporter
were fasted over night, anesthetized, and intravenously injected with either saline or 5U
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of human regular insulin (NovoNordisc) for 10 or 20 min. Mice were then perfused tran-
scardially with physiologic saline solution; brains were dissected, frozen in tissue freez-
ing medium (Jung Tissue Freezing MediumTM) and sectioned in 7 µM thick slices on a
cryostat (Leica, Germany). Tissues were stained with galactosidase (#55976; Cappel) and
PIP3 (#Z-G345; Echelon, FITC) and double fluorescence immunostaining was performed
as previously described (Plum et al. , 2006).
All slides were photographed through a Zeiss Axioskop equipped with a Zeiss Axio-
Cam for acquisition of digital images using Spot Advanced 3.0.3 software (Zeiss, Jena,
Germany).
2.3.2 Analysis of PiP3 accumulation in situ
For quantitative analysis of PiP3 levels in SF-1 neurons on NCD, a total of 13851 LacZ-
positive neurons was counted in VMH slices of SF-1lacZ control mice injected with saline,
(n = 2; 891 SF-1 neurons), 10 min insulin-stimulated control mice (n = 3, 1859 SF-1 neu-
rons), 20 min insulin-stimulated control mice (n = 2, 1637 SF-1 neurons), SF-1∆IR mice
injected with saline (n = 3; 1735 SF-1 neurons), 10 min insulin-stimulated SF-1∆IR mice
(n = 3, 1586 SF-1 neurons) and 20 min insulin-stimulated SF-1∆IR mice (n = 3, 1701 SF-1
neurons). For quantitative analysis of PiP3 levels in SF-1 neurons on HFD, a total of 4502
LacZ-positive neurons was counted in VMH slices of control mice injected with NaCl,
(n = 4; 2524 SF-1 neurons) and SF-1∆IR mice injected with NaCl (n = 3; 1978 SF-1 neu-
rons). The amount of PiP3 was classified either as low (immunoreactive cytoplasmatic
dots/sprinkles in the proximity of the nucleus at background levels, i.e., 4 or fewer dots,
no cloudy aspect, no confluent areas), moderate (dots/sprinkles at levels above back-
ground, i.e., more than 4 dots, cloudy aspect), or high (numerous dots/sprinkles, cloudy
with confluent areas). Slides were viewed through a Zeiss Axioskop equipped with a
Zeiss AxioCam for acquisition of digital images. Neurons positive for β-gal were counted
and marked digitally to prevent multiple counts, and PiP3 immunoreactivity was rated
as previously described (Könner et al. , 2007) using Zeiss AxioVision version 4.2 imaging
software. Results were calculated as percentage of SF-1 expressing neurons, which show
the respective PiP3 levels.
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2.3.3 Combined in situ hybridization and immunohistochemistry
For in situ hybridization combined with immunohistochemistry, series of 8µm coronal
sections of freshly frozen brains were sliced using a cryostat, thaw-mounted onto RNase-
free slides and stored at -80 ◦C until processing. Locked Nucleic Acid (LNA) RNA probe
detecting exon 4 of the insulin receptor gene (Insr) labeled at the 5’ and 3’ end with digox-
igenin was supplied by Exiqon (Vedbaek, Denmark). For in situ hybridization, brain
sections containing the VMH were fixed onto slides in 4% ice-cold PFA in PBS. Acety-
lation (5 µl*ml−1 acetic anhydride in 0.1 M triethanolamine) reduced nonspecific back-
ground signals. In an initial step (prehybridization), the slides were immersed in hy-
bridization buffer (50% (w/v) deionized formamide, Denhardt’s solution, 500 µg*ml−1
salmon sperm DNA, 500 µg*ml−1 tRNA) for 2.5 h at 48 ◦C to block nonspecific binding.
Hybridization was performed for at least 6 h at 48 ◦C in hybridization buffer contain-
ing 10% (w/v) dextran sulfate. Washes with increasing stringency were then performed.
To further remove unbound LNA probe, the brain slices were subjected to RNase A (0.5
µl*ml−1) digestion. In addition, to block nonspecific staining, slices were treated with 3%
(v/v) H2O2 in Tris-buffered saline and tyramide blocking solution. Specifically bound
probe was detected using a digoxigenin antibody coupled to peroxidase with cyanine-3
fluorophore–tyramide. After in situ hybridization, immunohistochemistry for detection
of β-galactosidase-positive neurons was performed as described (Belgardt et al. , 2008).
Finally, slides were covered with DAPI Mounting Shield (Vector Laboratories) to visu-
alize neurons. Images were taken using a Zeiss Meta Confocal microscope (Zeiss, Jena,
Germany).
Quantification of the IR signal was performed with ImageJ (US National Institutes
of Health) by converting the cyanine-3 fluorophore–tyramide signal into gray scale and
measuring mean gray values of the VMH in SF-1lacZ and SF-1∆IR:lacZ mice, using the β-
galactosidase signal as marker for the VMH. During these measurements, the area was
kept constant by using the “specify ROI” plug-in.
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2.3.4 Electrophysiology
Mice were anesthetized with halothane (B4388; Sigma-Aldrich) and decapitated. Coro-
nal slices (250 - 300 µm) containing the VMH and the ARC were cut with a vibrating
microtome (HM-650 V; Thermo Scientific) under cold (4 ◦C), carbogenated (95% O2 and
5% CO2), glycerol-based modified artificial cerebrospinal fluid (GaCSF) (Ye et al. , 2006).
GaCSF contained (in mM) 250 glycerol, 2.5 KCl, 2 MgCl2, 2 CaCl2, 1.2 NaH2PO4, 10
HEPES, 21 NaHCO3, 5 glucose, adjusted to pH 7.2 with NaOH.
If not mentioned otherwise, during the recordings the slices were continuously super-
fused with carbogenated aCSF at a flow rate of 2 ml*min−1. aCSF contained (in mM) 125
NaCl, 2.5 KCl, 2 MgCl2, 2 CaCl2, 1.2 NaH2 PO4, 21 NaHCO3, 10 HEPES, and 5 glucose ad-
justed to pH 7.2 with NaOH. Patch-clamp recordings were performed at 22 - 24 ◦C with
an EPC10 patch-clamp amplifier (HEKA). Data were sampled at intervals of 100 µs (10
kHz) and low-pass filtered at 2 kHz with a four-pole Bessel filter. Whole-cell capacitance
was determined by using the capacitance compensation (C-slow) of the EPC10. Cell in-
put resistances were calculated from voltage responses to hyperpolarizing current pulses.
The calculated liquid junction potential (14.6 mV) between intracellular and extracellular
solution was not compensated.
2.3.5 Electron microscopy
12 week old mice were anesthetized and perfused transcardially with saline followed
by Somogyi-Takagi fixative containg 4% paraformaldehyde and 0.8% glutaraldehyde in
0.1 M phosphate buffer. A tissue block containing the VMH and the ARC was dissected
from each brain. 50 µm thick vibratome sections were cut and thoroughly washed in
0.1 M phosphate buffer (PB). To eliminate unbound aldehydes, sections were incubated
in 1% sodiumborohydride for 15 min, and then rinsed in PB. Next, sections were incu-
bated in rabbit anti-GFP (Molecular Probes Inc., Eugene, OR) (dilution 1 : 1000 in PB)
for 24 h at room temperature. Subsequently, sections were incubated in biotinylated
goat anti- rabbit immunoglobulin (dilution 1 : 250; Vector Laboratories, Burlingame, CA,
USA) at room temperature. After washing in PB, sections were placed in avidin-biotin-
complex (ABC Elite Kit, Vector Labs) for 2 h at RT. The tissue-bound peroxidase was
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visualized by a diaminobenzidine reaction. After the immunostaining, the sections were
osmicated (15 min in 1% osmic acid in PB), and dehydrated in increasing ethanol concen-
trations. During the dehydration, 1% uranyl-acetate was added to the 70% ethanol to en-
hance ultrastructural membrane contrast. Dehydration was followed by flat-embedding
in Araldite. Ultrathin sections were cut on a microtome, collected on Formvar-coated
single-slot grids and analyzed with a Tecnai 12 Biotwin (FEI Company) electron micro-
scope. The quantitative analysis of synapse numbers was performed in a double-blind
fashion on electron micrographs from mice of different experimental groups. To ob-
tain a complementary measure of axo-somatic synaptic number, unbiased for possible
changes in synaptic size, the disector technique was used. On consecutive 90-nm-thick
sections, the average projected height of the synapses was determined and about 30%
of this value was used as the distance between the disectors. On the basis of this cal-
culation, the number of axo-somatic synapses was counted from 7 perikaryal profiles in
two consecutive serial sections roughly 270 nm apart (the "reference" and "look-up" sec-
tions) from each tissue block. In order to increase the sampling size, the procedure was
repeated in such a way that the reference and look-up sections were reversed. The num-
bers of symmetrical, asymmetrical and total contacts were collected independently from
serial sections. Synapse characterization was performed at 20000 magnification, while all
quantitative measurements were performed on electron micrographs at a magnification
of 11000. Symmetric and asymmetric synapses were counted on all selected neurons only
if the pre- and/or postsynaptic membrane specializations were clearly seen and synaptic
vesicles were present in the presynaptic bouton. Asymmetric synapses are formed by
axons that contain large vesicles and excitatory neurotransmitters (i.e. primarily gluta-
mate; excitatory synapses). In contrast, symmetric synapses have presynaptic axons with
small synaptic vesicles that contain the inhibitory transmitter GABA. The presynaptic
and postsynaptic densities of these synapses are approximately of equal thickness (in-
hibitory synapses). Synapses with neither clearly symmetric nor asymmetric membrane
specializations were excluded from the assessment. The plasma membranes of selected
cells were outlined on photomicrographs and their length was measured with the help
of a chartographic wheel. Plasma membrane length values measured in the individual
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animals were added and the total length was corrected to the magnification applied. The
synaptic counts were expressed as numbers of synapses on a membrane length unit of
100 µm.
2.4 Biochemistry
2.4.1 Protein extraction
Shock-frozen tissues were thawed and homogenized in lysis buffer (50 mM HEPES (pH
7.4), 1% Triton X-100, 0.1 M NaF, 10 mM EDTA, 50 mM NaCl, 10 mM Na3O4V, 0.1% SDS,
10 µg/ml Aprotinin, 2 mM Benzamidine, 2 mM PMSF) using a Ultrathurrax homogenizer
(IKA Werke, Staufen, Germany). Particulate matter was removed by centrifugation for 1
h at 4◦C. The supernatant was transferred to a new reaction tube and protein concentra-
tions were determined by measuring the sample absorption at 280 nm with a NanoDrop
ND-1000 UV- Vis Spectrophotometer (Peqlab, Erlangen, Germany). Proteins that contain
tryptophane, tyrosine residues or cysteine-cysteine disulphide bonds absorb in the UV
range of 280 nm. Subsequently, protein extracts were diluted to 10 mg/ml with lysis
buffer and 4 x SDS sample buffer (125 mM Tris- HCl (pH 6.8), 5% SDS, 43.5% glycerol,
100 mM DTT, and 0.02% bromphenol blue), incubated at 95◦C for 5 min and stored at
-80◦C.
2.4.2 Western blot analysis
Frozen protein extracts were thawed at 95◦C for 5 min, then separated on 10% (v/v) SDS
polyacrylamide gels and semi-dry blotted onto PVDF membranes (Bio-Rad, München,
Germany). Membranes were then incubated with 1% blocking reagent (Roche, Mannheim,
Germany) for 1 h at RT or overnight at 4◦C. Subsequently, primary antibodies (table 2.3)
diluted in 0.5% blocking solution were applied for 1 h at RT or overnight at 4◦C. PVDF
membranes were then washed three times for 15 min with 1 x TBS/1%Tween. After 1
h incubation at RT with the respective secondary antibodies, membranes were washed
three times for 15 min with 1 x TBS/1%Tween, incubated for 1 min in Pierce ECL Western
Blotting Substrate (Perbio Science, Bonn, Germany), sealed in a plastic bag and exposed
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to chemiluminescence films (Amersham, Braunschweig, Germany). Films were devel-
oped in an automatic developer (Kodak, Stuttgart, Germany).
Table 2.3: Primary western blot antibodies
Antigen Catalogue Nr. Distributor Dilution
β-actin #A5441 Sigma Aldrich, Seelze, Germany 1:10000
α-tubulin #T6074 Sigma Aldrich, Seelze, Germany 1:5000
IR-β sc-711 Cell signaling, Danvers, USA 1:500
2.4.3 Enzyme-linked immunosorbent assays (ELISA)
Serum insulin, leptin and testosterone, as well as plasma corticosterone, epinephrine and
norepinephrine concentrations were measured by ELISA according to manufacturer’s
guidelines (Mouse Leptin ELISA, Mouse/Rat Insulin ELISA, Crystal Chem, Downers
Grove, USA; Corticosterone Enzyme Immunoassay Kit, Assay Designs Inc., Ann Arbor,
USA; Epinephrine EIA, Norepinephrine EIA, DRG Instruments, Heidelberg, Germany).
For evaluation of glucagon plasma levels, an radioimmunoassay (RIA) was performed
according to manufacturer’s guidelines Glucagon RIA Kit, #GL-32K, LINCO Research,
St.Charles, USA).
2.5 Computer analysis
2.5.1 Densitometrical analysis
Protein expression was assessed by Western blot analysis and bands were measured in
intensity per mm2 using the Quantity One Software (Bio-Rad, München, Germany). Af-
ter background subtraction, each sample was normalized to an internal loading control.
Average protein expression of control mice was set to 100% and compared to protein
expression of knockout animals unless stated otherwise.
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2.5.2 Statistical methods
Data sets were analyzed for statistical significance using a two-tailed unpaired student’s
t-test. All p values below 0.05 were considered significant. All displayed values are
means ± S.E.M.. * p ≤ 0.05 ; ** p ≤ 0.01 ; *** p ≤ 0.001 versus controls.
2.6 Chemicals and biological material
Size markers for agarose gel electrophoresis (Gene RulerTM DNA Ladder Mix) and for
SDS-PAGE (Page RulerTM Prestained Protein Ladder Mix) were obtained from MBI Fer-
mentas, St. Leon-Rot, Germany. RedTaq DNA Polymerase and 10x RedTaq buffer were
purchased from Sigma-Aldrich, Seelze, Germany. All chemicals used in this work are
listed in table 1 and all enzymes used in this work are listed in tables 2.4, 2.5 and 2.6.
Solutions were prepared with double distilled water.
Table 2.4: Chemicals 1
Chemical Supplier
β-mercaptoethanol Applichem, Darmstadt, Germany
e-aminocaproic acid Sigma-Aldrich, Seelze, Germany
0.9% saline (sterile) Delta Select, Pfullingen, Germany
2,2,2-Tribromoethanol (Avertin) Sigma-Aldrich, Seelze, Germany
2-Methyl-2-Butanol Sigma-Aldrich, Seelze, Germany
Acetic acid Merck, Darmstadt, Germany
Acetone KMF Laborchemie, Lohmar, Germany
Acrylamide Roth, Karlsruhe, Germany
Agarose Peqlab, Erlangen, Germany
Agarose (Ultra Pure) Invitrogen, Karlsruhe, Germany
Ammonium Acetate Merck, Darmstadt, Germany
Ammoniumpersulfat (APS) Sigma-Aldrich, Seelze, Germany
Aprotinin Sigma-Aldrich, Seelze, Germany
Avidin Biotin Complex-Vectastain Elite Vector, Burlingame, USA
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Table 2.5: Chemicals 2
Chemical Supplier
Bacillol Bode Chemie, Hamburg, Germany
Barium hydroxide Sigma-Aldrich, Seelze, Germany
Benzamidine Sigma-Aldrich, Seelze, Germany
Bovine serum albumin (BSA) Sigma-Aldrich, Seelze, Germany
Bromphenol blue Merck, Darmstadt, Germany
Calcium chloride Merck, Darmstadt, Germany
Chloroform Merck, Darmstadt, Germany
Desoxy-ribonucleotid-triphosphates (dNTPs) Amersham, Freiburg, Germany
Diaminobenzidin (DAB) Dako, Kopenhagen, Denmark
Dimethylsulfoxide (DMSO) Merck, Darmstadt, Germany
di-Natriumhydrogenphosphat Merck, Darmstadt, Germany
Enhanced chemiluminescence (ECL) Kit Perbio Science, Bonn, Germany
Ethanol, absolute Applichem, Darmstadt, Germany
Ethidium bromide Sigma-Aldrich, Seelze, Germany
Ethylendiamine tetraacetate (EDTA) Applichem, Darmstadt, Germany
Forene (isoflurane) Abbot GmbH, Wiesbaden, Germany
Glucose 20% DeltaSelect, Pfullingen, Germany
Glycerol Serva, Heidelberg, Germany
Glycine Applichem, Darmstadt, Germany
Halothane Sigma-Aldrich, Seelze, Germany
HEPES Applichem, Darmstadt, Germany
Hydrochloric acid (37%) KMF Laborchemie, Lohmar, Germany
Hydrogen peroxide Sigma-Aldrich, Seelze, Germany
Insulin Novo Nordisk, Bagsvaerd, Denmark
Isopropanol (2-propanol) Roth, Karlsruhe, Germany
Kaisers Glycerin Gelatine Merck, Darmstadt, Germany
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Table 2.6: Chemicals 3
Chemical Supplier
Leptin, recombinant NHPP, Torrence, USA
Magnesium chloride Merck, Darmstadt, Germany
Methanol Roth, Karlsruhe, Germany
Nitrogen (liquid) Linde, Pullach, Germany
Octenisept Schülke & Mayr, Norderstedt, Germany
Paraformaldehyde (PFA) Sigma-Aldrich, Seelze, Germany
Phenylmethylsulfonylfluoride (PMSF) Sigma-Aldrich, Seelze, Germany
Phosphate buffered saline (PBS) Gibco BRL, Eggenstein, Germany
Potassium chloride Merck, Darmstadt, Germany
Potassium hydroxide Merck, Darmstadt, Germany
Sodium acetate Applichem, Darmstadt, Germany
Sodium chloride Applichem, Darmstadt, Germany
Sodium citrate Merck, Darmstadt, Germany
Sodium dodecyl sulfate Applichem, Darmstadt, Germany
Sodium fluoride Merck, Darmstadt, Germany
Sodium heparin (Liquemin) Roche, Grenzach-Wyhlen, Switzerland
Sodium hydroxide Applichem, Darmstadt, Germany
Sodium orthovanadate Sigma-Aldrich, Seelze, Germany
Sucrose Applichem, Darmstadt, Germany
Tetramethylethylenediamine (TEMED) Sigma-Aldrich, Seelze, Germany
Tissue Freezing Medium Jung, Heidelberg, Germany
Tramadolhydrochlorid (Tramal) Grünenthal, Aachen, Germany
Trishydroxymethylaminomethane (Tris) Applichem, Darmstadt, Germany
Triton X-100 Applichem, Darmstadt, Germany
Tween 20 Applichem, Darmstadt, Germany
Vectashield Mounting Medium with DAPI Vector, Burlingame, USA
Western Blocking Reagent Roche, Mannheim, Germany
Zinc sulfate Sigma-Aldrich, Seelze, Germany
41
3 Results
3.1 Generation of SF-1 specific insulin receptor knockout mice
To investigate the role of insulin signaling in SF-1 neurons in the VMH in the CNS me-
diated control of energy homeostasis, transgenic mice that express the Cre recombinase
under control of the SF-1 promotor (Dhillon et al. , 2006) were crossed with mice with
loxP-site flanked exon 4 of the insulin receptor gene (Brüning et al. , 1998) (figure 3.1).
Exon IV 
IR 3’ IR 5’ del IR 5’ 
IR 3’ IR 5’ del 
Cre-mediated 
recombination 
Cre - polyA 
SF1 5’ SF1 3’ 
A 
B 
Ex I Ex II Ex III Ex IV Ex V Ex VI Ex VII 
ATG 
32 kb upstream 
of Sf-1 
106 kb downstream 
of Sf-1 
Figure 3.1: Scheme of SF-1 Cre mediated recombination of the insulin receptor allele.
(A) Transgenic SF-1 Cre construct generated by Dhillon et al. (2006). (B) Exon 4 of the insulin
receptor flanked by loxP-sites. Cre mediated recombination leads to the excision of exon 4, which
results in a frameshift mutation and thereby introduces a pre-mature stop codon. This results in
severely truncated insulin receptor mRNA, which is degraded by the nonsense-mediated decay
mechanism in the Cre-expressing cells (Brüning et al. , 1998). Depicted by arrows are the PCR
primers used for genotyping of the alleles, triangles represent loxP-sites.
In cells, that express the Cre recombinase, exon 4 of the insulin receptor gene is excised,
leading to a pre-mature stop-codon. The severely truncated insulin receptor mRNA is
then degraded by nonsense-mediated decay mechanisms. Even if the nonsense-mediated
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decay fails and remaining mRNA is translated, the lack of the transmembrane domain
will lead to a non-functional receptor.
To confirm the VMH-specific expression of the SF-1 Cre transgene, these mice were
also crossed to RosaArte1 and Z/eG mice (Novak et al. , 2000; Seibler et al. , 2003). Due
to the fact that SF-1 gene expression is also reported in the adrenal gland, pituitary gland
and testis, IHC was performed using the aforementioned reporter strains to visualize the
magnitude of expression in this tissues. Figure 3.2 shows massive recombination in the
VMH (3.2 A), but little expression was also seen in the cerebral cortex (not shown). In the
pituitary gland, GFP positive cells were found, although to a much lesser extend (3.2 B).
Furthermore, in the cortex of the adrenal gland (3.2 C) and in Sertoli cells in the testis (3.2
D) of SF-1GFP mice little Cre expression was observed.
A	   B	  
C	   D	  
Figure 3.2: Immunohistochemistry using peroxidase-coupled GFP antibodies to visualize Cre ex-
pression in SF-1GFP mice in the brain and peripheral organs. β-galactosidase was stained in SF-
1lacZ and SF-1lacZ:∆IR mice and positive neurons were counted.
(A) GFP expression in the VMH of SF-1GFP mice. (B) GFP expression in the pituitary gland.
(C) GFP expression in the adrenal gland. (D) GFP expression in the testis.
Due to the fact that expression of endogenous Sf-1 is reported in several peripheral tis-
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sues (Parker et al. , 2002), western blot analysis was performed of metabolically relevant
tissues to exclude any effects of IR deletion in peripheral organs. As shown in figure 3.3,
no major alterations were observed in the expression levels of the IR between control and
SF-1∆IR mice. Although the SF-1 Cre is mainly expressed in the VMH of the hypothala-
mus, IR protein levels did not differ in whole-hypothalamus and the same holds true for
peripheral organs and the pituitary gland, where no or little Cre expression was observed
or reported.
Figure 3.3: Western blot analysis of brain and peripheral tissue lysates from control and SF-1∆IR
mice for the β-subunit of the IR and α-tubulin or β-actin as loading control.
BAT, brown adipose tissue; HT, hypothalamus; Pit, pituitary gland; Panc, pancreas; RB, remaining
brain without the hypothalamus; SM, skeletal muscle; WAT, white adipose tissue.
Owing to the expression pattern of the SF-1 Cre in the hypothalamus, the pituitary
gland, Sertoli cells in testis and in Leydig cells of ovaries of SF-1∆IR animals (Ikeda et al.
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, 1994), the reproductive ability of both SF-1∆IR males and females was assessed by the
evaluation of breeding success. To this end, male and female SF-1∆IR animals were bred
with the respective control IR f l/ f l mice and average litter size and average litter fre-
quency were analyzed. As shown in figure 3.4A and B, neither average litter size nor
average litter frequency differed between the genotypes.
Furthermore, quantitative real-time PCR analysis was performed on pituitary gland
cDNA to investigate the effect of IR deficiency in the VMH on key hormones of the
hypothalamic-pituitary-gonadal (HPG) axis. Hence, the expression levels of follicle-stimulating
hormone (Fshβ), luteinizing hormone (Lhβ), thyroid-stimulating hormone (Tshβ) and
growth hormone (Gh) were determined. Figure 3.4C indicates no differences in the ex-
pression levels of pivotal hormones of the HPG axis between control and SF-1∆IR male
mice. This was further confirmed by the analysis of free triiodothyronine (T3) levels in
the serum of control and SF-1∆IR males, where no alteration were detectable (3.4D). Thus,
the IR deficiency of SF-1 neurons did not affect fertility or the HPG axis.
As the IR shares a high homology with the insulin-like growth factor 1 receptor (IGF-
1R) and shares a high homology to other receptor tyrosine-kinases, there are no appro-
priate antibodies available for the detection of the IR with IHC methods. Thus, in situ
hybridization (ISH) was performed on hypothalami of control SF-1lacZ and SF-1lacZ:∆IR
animals. The in situ probe was designed against the exon 4 of the insulin receptor gene for
being able to distinguish between control and SF-1∆IR genotypes. Additionally, the exon
4 encodes for a subunit of the ligand-binding domain of the IR, therefore providing high-
est specificity for the in situ probe (red). The analyzed sections were co-stained against
β-galactosidase to visualize SF-1 Cre expressing neurons (green) and with DAPI to vi-
sualize the nuclei of the surrounding neurons (blue). Figure 3.5A shows representative
sections of control and SF-1lacZ:∆IR brain slices. Subsequently, the insulin receptor mRNA
signal was quantified in SF-1lacZ:∆IR compared to controls using ImageJ (NIH), verifying
the successful deletion of the insulin receptor gene (figure 3.5B).
To address if the deficiency for the IR in SF-1∆IR mice also translates into functional
down-regulation of the PI3K pathway, immunohistochemistry (IHC) staining for the sec-
ond messenger of the PI3K pathway, PiP3, were performed. To this end mice were either
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Figure 3.4: Fertility and function of the HPG axis was investigated in control and SF-1∆IR knock-
out animals.
(A) Average littersize of breedings with male control (n = 3, 10 litters) and SF-1∆IR (n = 3, 14 lit-
ters). (B) Average time between litter of breedings with control (n = 3, 10 litters) and SF-1∆IR (n =
3, 14 litters). (C) Quantitative real-time PCR analysis for expression levels of follicle-stimulating
hormone (Fshβ), luteinizing hormone (Lhβ), thyroid-stimulating hormone (Tshβ) and growth hor-
mone (Gh) in pituitary gland cDNA of control (n = 6) and SF-1∆IR knockout (n = 6) males. (D)
Free triiodothyronine (T3) levels in the serum of control (n = 20) and SF-1∆IR (n = 20) males.
Displayed values are means ± S.E.M..
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Figure 3.5: In situ hybridization (ISH) against Insulin receptor mRNA in control (SF-1lacZ) and SF-
1lacZ:∆IR animals. The ISH probe was designed against the exon 4 of the insulin receptor gene that
is deleted upon Cre mediated recombination and thus will not detect remaining mRNA of the
insulin receptor. Exon 4 encodes for a subunit of the ligand binding domain, hence providing a
high specificity.
(A) Representative sections of controls and SF-1∆IR brain slices. Insulin receptor mRNA (red), anti-
β-galactosidase immuno staining (green) and counterstaining for nuclei with DAPI (blue). Scale
bar, 10 µm. (B) Quantification of the VMH InsR mRNA signal normalized to controls.
Displayed values are means ± S.E.M.; *, p ≤ 0.05.
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injected with saline into the vena cava inferior, or stimulated for 10 or 20 min with 5U of hu-
man insulin. After the stimulation, both control (SF-1lacZ) and SF-1lacZ:∆IR mice were tran-
scardiacally perfused with PBS and subsequently stained for PiP3 and β-galactosidase as
marker for Cre-mediated recombination. PiP3 levels were analyzed as described in Kön-
ner et al. (2007).
As shown in figure 3.6A, 56% of the SF-1 neurons in SF-1lacZ mice showed low PiP3
levels when injected with saline (35% showed moderate PiP3 and 9% high levels). Upon
10 min of insulin stimulation, 57% of SF-1 neurons shifted to moderate PiP3 levels, whereas
only 19% remained on a low level and already 24% even showed high PiP3 accumulation
around the nucleus. When mice were finally stimulated for 20 min with 5U of insulin the
majority of SF-1 neurons displayed high (43%) or moderate (44%) PiP3 levels and only
13% remained on a low level. Prolonged insulin stimulation resulted in a shift towards
higher PiP3 levels in SF-1 neurons of SF-1lacZ animals.
In contrast to SF-1lacZ control mice, the shift towards higher PiP3 levels was completely
abolished in SF-1lacZ:∆IR mice, that lack the IR on SF-1 neurons. Figure 3.6B indicates that
neither 10 min nor 20 min insulin stimulation resulted in a shift towards high or even
moderate PiP3 levels. Baseline PiP3 levels after saline injection were mainly low (83% of
SF-1 neurons low) and even after insulin stimulation for 10 min (86% low) or 20 min (81%
low), no activation of PiP3 formation could be observed.
Figure 3.6C upper panel shows representative images of control SF-1lacZ and SF-1lacZ:∆IR
knockout brain slices, injected with saline or either stimulated for 10 min or 20 min with
5U of human insulin, respectively. In the lower panel, exemplary images for PiP3 lev-
els of neurons with low, moderate or high levels are depicted. PiP3 is visualized in red,
β-galactosidase in green and counterstaining for the nuclei with DAPI is shown in blue.
Due to the fact that insulin and especially the PI3K signaling pathway are survival
signals for cells, number of SF-1 neurons was investigated in control SF-1lacZ and SF-
1lacZ:∆IR males. As depicted in figure 3.6D, numbers of β-gal positive neurons did not
differ between the genotypes.
Taken together, Cre mediated recombination was verified in the VMH, pituitary gland,
adrenal gland and testis of SF-1GFP reporter animals (figure 3.2A - D). Besides, scattered
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Figure 3.6: Double immunohistochemistry (IHC) staining for PiP3 levels and β-galactosidase as
marker for Cre-positive neurons in saline injected, 10 min or 20 min insulin-stimulated SF-1lacZ
control and SF-1lacZ:∆IR knockout animals.
(A) Quantification of PiP3 levels in saline treated (n = 2; 891 SF-1 neurons), 10 min (n = 3, 1859
SF-1 neurons) or 20 min (n = 2, 1637 SF-1 neurons) insulin-stimulated SF-1lacZ control animals.
Displayed are percentages of neurons showing the respective PiP3 levels for each stimulus. (B)
Quantification of PiP3 levels in saline treated (n = 3; 1735 SF-1 neurons), 10 min (n = 3, 1586 SF-1
neurons) or 20 min (n = 3, 1701 SF-1 neurons) insulin-stimulated SF-1lacZ:∆IR knockout animals.
Displayed are percentages of neurons showing the respective PiP3 levels for each stimulus. (C)
Upper panel Representative images of PiP3 formation in the VMH of SF-1lacZ reporter and SF-
1lacZ:∆IR knockout mice. Scale bar, 10 µm. Lower panel PiP3 immunoreactivity magnitudes as
described in Material & Methods. PiP3 (green), β-galactosidase (red) and DAPI (blue). (D) Num-
bers of SF-1 neurons in VMH slices of SF-1lacZ and SF-1lacZ:∆IR mice.
Displayed values are means ± S.E.M.; *, p ≤ 0.05; ***, p ≤ 0.001.
Cre expression was also observed in the spleen and ovaries (personal observation). De-
spite this expression pattern of the SF-1 Cre, no alterations in IR protein expression could
be observed in brain lysates and metabolically relevant peripheral organs (figure 3.3).
Furthermore, the number of SF-1 Cre positive neurons was not affected by the Cre-
mediated IR deficiency (3.6D). Likewise, fertility was unchanged between control and
SF-1∆IR mice and the functionality of the HPG axis was confirmed (figure 3.4). How-
ever, SF-1 Cre mediated recombination results in a reduced expression of insulin receptor
mRNA, proven by in situ hybridization (figure 3.5). That the reduced expression also
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translates into a efficient downregulation of the PI3K pathway was verified using im-
munohistochemical stainings for the second messenger in this pathway, PiP3 (figure 3.6).
3.2 Insulin silences VMH SF-1 neurons via KATP channels
Using SF-1GFP mice, the effects of insulin stimulation on the electrophysiological prop-
erties were studied. To determine the insulin responsiveness of SF-1 neurons and SF-
1 neurons that lack the insulin receptor (SF-1GFP:∆IR neurons), perforated patch clamp
recordings were performed to ensure the integrity of intracellular components (figure
3.7A). Basic biophysical properties such as whole-cell capacitance, membrane potential,
firing rate and input resistance were not significantly different between SF-1 neurons of
the two genotypes (table 3.1).
Table 3.1: Electrophysiological parameters of SF-1 neurons in SF-1GFP and SF-1GFP:∆IR mice.
Whole-cell Firing rate Membrane potential Input resistance
capacitance (pF) (Hz) (mV) (GΩ)
SF-1GFP 12.5 ± 1.0 3.5 ± 0.5 -46.8 ± 1.0 1.24 ± 0.12
(n = 14) (n = 13) (n = 14) (n = 14)
SF-1GFP:∆IR 16.5 ± 1.8 2.9 ± 0.5 -48.5 ± 1.7 1.51 ± 0.24
(n = 12) (n = 9) (n = 12) (n = 11)
Insulin inhibited 43% (6 of 14) of the SF-1GFP neurons (figure 3.7C) recorded from the
medio-basal VMH, where most of the insulin-stimulated PiP3 formation was detectable.
In the subset of insulin-responsive neurons, the membrane potential significantly hyper-
polarized upon insulin stimulation from -48.2 ± 0.7mV to -54.1 ± 1.7mV (n = 6; p < 0.05;
figure 3.7D) and the firing rate was significantly reduced from 2.2 ± 0.5 Hz to 0.7 ± 0.5
Hz (n = 5; p < 0.05; figure 3.7D). Application of the specific KATP channel antagonist
tolbutamide along with insulin resulted in the recovery of membrane potential and fir-
ing rate to control values (figure 3.7D). In contrast, none of the SF-1GFP:∆IR neurons were
inhibited by insulin (0 of 12; figure 3.7C). Of note, insulin induced excitation in one of the
SF-1GFP neurons and two of the SF-1GFP:∆IR neurons. Taken together, our results indi-
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cate that insulin modulates the biophysical properties in a subset of SF-1 VMH neurons
in a similar manner as it does for POMC neurons in the ARC.
Figure 3.7: Perforated patch-clamp recordings were performed of GFP positive neurons from SF-
1GFP and SF-1GFP:∆IR mice.
(A) Representative recording trace of an identified insulin-responsive SF-1-positive neuron in a
hypothalamic slice from an SF-1GFP mouse before and during addition of 200 nM insulin, fol-
lowed by application of 200 µM tolbutamide (tolbut.). (B) Representative recording trace of an
identified SF-1-positive a neuron from a SF-1GFP:∆IR mouse before and during addition of 200 nM
insulin, followed by application of 200 µM tolbutamide. (C) Percentage of insulin-responsive SF-1
neurons from SF-1GFP mice and SF-1GFP:∆IR mice. (D) Left panel Membrane potential of identified
SF-1 neurons in hypothalamic slices from SF-1GFP before and during application of 200 nM in-
sulin, followed by addition of 200 µM tolbutamide (n = 6 neurons per group). Right panel Firing
frequency of identified SF-1 neurons in hypothalamic slices from SF-1GFP mice before and dur-
ing application of 200 nM insulin, followed by addition of 200 µM tolbutamide (n = 5 neurons per
group). (E) Left panel Membrane potential of identified SF-1 neurons from SF-1GFP:∆IR mice before
and during application of 200 nM insulin, followed by addition of 200 µM tolbutamide (n = 12
neurons per group). Right panel Firing frequency of identified SF-1 neurons from SF-1GFP:∆IR mice
before and during application of 200 nM insulin, followed by addition of 200 µM tolbutamide (n
= 9 neurons per group).
Displayed values are means ± S.E.M.; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001.
3.3 Insulin and leptin responsive SF-1 neurons are distinct
sub-populations
To address whether leptin-regulated SF-1 VMH neurons and insulin-regulated SF-1 VMH
neurons might segregate into distinct populations, whole-cell patch clamp electrophysi-
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ological recordings from identified SF-1 VMH neurons were performed with individual
or sequential application of leptin and insulin (tables 3.2, 3.3 and 3.4). Experiments were
performed in collaboration with Joel K. Elmquist and Kevin W. Williams. Tables are
adapted from Klöckener et al. (2011).
Table 3.2: Responses of SF-1 neurons to leptin and insulin.
Leptin Insulin
Depolarized 8 (11.4%) 0 (0%)
Hyperpolarized 14 (20.0%) 5 (13.2%)
No response 48 (68.6%) 33 (86.8%)
Total 70 (100%) 38 (100%)
This analysis revealed that SF-1 VMH neurons that depolarized upon leptin stimula-
tion did not decrease firing frequency upon subsequent insulin stimulation and that 3 of
21 neurons, which did not respond to leptin, hyperpolarized upon subsequent insulin
stimulation (table 3.3).
Table 3.3: Responses of SF-1 neurons to sequential leptin and insulin double application.
Leptin 1st
Depolarized No response
Insulin 2nd Hyperpolarized 0 3
No response 2 18
Total 2 21
Moreover, 1 of 16 neurons that did not to respond to insulin depolarized upon subse-
quent leptin treatment, and 5 of 16 neurons that did not respond to insulin hyperpolar-
ized upon subsequent leptin application (table 3.4).
Collectively, these experiments provide evidence that leptin and insulin responses of
SF-1 VMH neurons are likely to segregate, probably representing two distinct neuronal
populations.
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Table 3.4: Responses of SF-1 neurons to sequential insulin and leptin double application.
Insulin 1st
No response
Leptin 2nd Depolarized 1
Hyperpolarized 5
No response 10
Total 16
3.4 Attenuated obesity in SF-1∆IR mice upon high-fat diet
feeding
To investigate the effect of insulin receptor deficiency in VMH SF-1 neurons on energy
homeostasis, control (IR f l/ f l) and SF-1∆IR were fed either a normal-chow (NCD) or a
high-fat diet (HFD) for 16 weeks after weaning. Under NCD conditions, no alterations
could be observed in the body weight of control and SF-1∆IR males (figure 3.8A triangles)
and females (personal observation). Accordingly, neither total body fat content nor epig-
onadal fat pad weight did differ between the genotypes on NCD in male (figure 3.8B and
C) and female mice (personal observation).
Upon HFD feeding, male control mice showed significantly increased body weight after
3 weeks when compared to control males fed a NCD. In contrast, HFD-fed SF-1∆IR males
were completely protected against the high-fat diet induced weight gain until 14 weeks of
age. Only from 15 weeks of age on, a difference was observed between NCD-fed controls
and SF-1∆IR fed a HFD, whereas SF-1∆IR on HFD remained significantly lighter when
compared to HFD-fed controls (figure 3.8A). In line with this findings, SF-1∆IR males fed
a HFD displayed reduced epigonadal fat pad weight and total body fat content measured
by nuclear magnetic resonance spectography as compared to HFD-fed control males at
the age of 20 weeks (figure 3.8B, C).
To confirm that the lower body weight results from reduced adiposity, serum leptin
levels were measured in 8 and 20 weeks old control and SF-1∆IR males, both fed NCD and
HFD. As shown in figure 3.9A, leptin levels are significantly lower in HFD fed SF-1∆IR
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Figure 3.8: SF-1∆IR are protected against HFD- induced weight gain.
(A)Average body weight curve of control and SF-1∆IR fed either normal chow diet (NCD) or high-
fat diet (HFD) over the period of 16 weeks (n > 15 per genotype and diet). (B) Average epigonadal
fat pad weight of control and SF-1∆IR animals on NCD and HFD at the age of 20 weeks (n > 15 per
genotype and diet). (C) Average total body fat content of control and SF-1∆IR animals on NCD
and HFD at the age of 20 weeks (n > 15 per genotype and diet).
Displayed values are means ± S.E.M.; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; §, p ≤ 0.01 for the
body weight curve.
males compared to controls, both at 8 and 20 weeks of age. To examine the expansion of
the epigonadal white adipose tissue (WAT), sections of WAT were analyzed according to
the size of the adipocytes. As shown in figure 3.9B and C, the average size of adipocytes
in 20 week old SF-1∆IR males was decreased in comparison to control animals on HFD.
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Figure 3.9: Reduced adiposity in HFD-fed SF-1∆IR males.
(A) Average serum leptin levels of control and SF-1∆IR fed either NCD or HFD at the age of 8 and
20 weeks (n > 15 per genotype and diet). (B) Average size of adipocytes in the epigonadal white
adipose tissue (WAT) of control and SF-1∆IR animals on NCD and HFD at the age of 20 weeks
(n > 3 per genotype and diet). (C) Representative images of H&E stained sections from WAT of
control and SF-1∆IR on HFD at the age of 20 weeks. Scale bar, 100 µm.
Displayed values are means ± S.E.M.; *, p ≤ 0.05; **, p ≤ 0.01.
3.5 Reduced food intake as consequence of increased leptin
sensitivity in young SF-1∆IR mice
As alterations in energy homeostasis can be caused by food intake, energy expenditure
or both, it was investigated if these factors are altered by the ablation of the IR in SF-1
neurons in the VMH. To this end, young (6 - 7 weeks of age) and older (12 - 13 weeks)
control and SF-1∆IR males on HFD were analyzed for daily caloric intake, O2 consump-
tion and CO2 production by means of indirect calorimetry. This analysis revealed that
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young SF-1∆IR, that did not differ in body weight from controls, showed no alterations
in O2 consumption, CO2 production or food intake (figure 3.10).
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Figure 3.10: Unaltered energy expenditure and food intake of 6 to 7 week old control and SF-1∆IR
males on HFD measured by indirect calorimetry.
(A) Average O2 consumption normalized to lean mass of control and SF-1∆IR on HFD at the age
of 6 to 7 weeks (n > 16 per genotype). (B) Average CO2 production normalized to lean mass of
control and SF-1∆IR on HFD at the age of 6 to 7 weeks (n > 16 per genotype). (C) Average food
intake per day of control and SF-1∆IR on HFD at the age of 6 to 7 weeks (n > 16 per genotype).
Displayed values are means ± S.E.M..
In contrast, older SF-1∆IR males showed a significantly decreased absolute food in-
take when compared to controls (figure 3.11C), whereas both O2 consumption and CO2
production remained unchanged when normalized to lean mass (figure 3.11A and B).
However, if the food intake was normalized for the alterations in body weight, no obvi-
ous changes were detected anymore.
In line with the previous findings, neither locomotor activity nor respiration rate were
altered in HFD-fed SF-1∆IR at both ages (personal observation).
To address whether the decreased body weight and absolute food intake in older SF-
1∆IR males results from alterations in leptin’s ability to reduce food intake, 7 to 8 week
old HFD-fed controls and SF-1∆IR males were fasted overnight. Subsequently, they were
injected with either artificial cerebrospinal fluid (aCSF) or 5 µg leptin intracerebroven-
tricularly (icv) and food intake was monitored for 8 hours. Of note, animals used for this
study did not display any differences in body weight. As depicted in figure 3.12, leptin
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Figure 3.11: Unaltered energy expenditure and food intake of 12 to 13 week old control and SF-
1∆IR males on HFD measured by indirect calorimetry.
(A) Average O2 consumption normalized to lean mass of control and SF-1∆IR on HFD at the age of
13 to 14 weeks (n > 14 per genotype). (B) Average CO2 production normalized to mass of control
and SF-1∆IR on HFD at the age of 13 to 14 weeks (n > 14 per genotype). (C) Average absolute food
intake per day of control and SF-1∆IR on HFD at the age of 12 to 13 weeks (n > 14 per genotype).
(D) Average daily food intake normalized for body weight of control and SF-1∆IR on HFD at the
age of 12 to 13 weeks (n > 14 per genotype).
Displayed values are means ± S.E.M.; *, p ≤ 0.05.
was able to reduce food intake significantly further in SF-1∆IR males when compared to
controls.
These results indicate an increased leptin sensitivity in SF-1∆IR mice, already before
the onset of changes in body weight and absolute food intake.
3.6 Improved glucose metabolism in SF-1∆IR mice upon
HFD-feeding
Previously, it could be shown that insulin’s action in the CNS regulates peripheral glu-
cose homeostasis (Koch et al. , 2008; Könner et al. , 2007; Obici et al. , 2002a; Pocai et al.
, 2005), what is attenuated in conditions of diet-induced obesity (Belgardt et al. , 2010;
Kleinridders et al. , 2009). Hence, intraperitoneal (i.p.) glucose tolerance tests and insulin
tolerance tests were performed in 15 week old control and SF-1∆IR animals under NCD
conditions and furthermore blood glucose levels and serum insulin concentrations were
56
3 Results
aCSF Leptin aCSF Leptin aCSF Leptin aCSF Leptin
0.0
0.5
1.0
1.5
SF-1!IR
Control
4 hr 8 hr
*
*
Fo
od
 in
ta
ke
 [g
]
Figure 3.12: 7 to 8 week old, body weight matched, control and SF-1∆IR males on HFD were
starved over night and subsequently intracerebroventricularly injected with either artificial cere-
brospinal fluid (aCSF) or 5 µg leptin. Food intake was then monitored for 8 hours after re-feeding
(n > 5 per genotype).
Displayed values are means ± S.E.M.; *, p ≤ 0.05 in an unpaired, one-tailed student’s t-test.
determined. The analysis revealed no alterations upon insulin receptor deficiency in the
VMH on glucose homeostasis in both genotypes (figure 3.13).
Thus, the lack of insulin receptors on SF-1 neurons in the VMH does not alter periph-
eral glucose metabolism under NCD conditions.
When control and SF-1∆IR mice were exposed to HFD feeding, SF-1∆IR males revealed
an improved glucose metabolism. Whereas blood glucose levels remained unchanged
(figure 3.14A), insulin levels were significantly lower in SF-1∆IR males (figure 3.14B) at
the age of 20 weeks. Moreover, both insulin sensitivity and glucose tolerance were im-
proved at 15 and 16 weeks of age (figure 3.14C and D). Although fasted and random-fed
blood glucose did not differ, SF-1∆IR males on HFD showed an improved insulin stim-
ulated glucose clearance from the circulation upon injection with human insulin (figure
3.14C). Furthermore, SF-1∆IR males also showed an improved glucose clearance from the
bloodstream after an i.p. injection of glucose (figure 3.14D).
Under NCD-conditions, insulin receptor deficiency does not alter peripheral glucose
metabolism. Neither blood glucose levels, serum insulin concentrations, insulin stimu-
lated glucose uptake nor glucose clearance from the circulation revealed any differences
between the genotypes. Upon HFD-feeding, blood glucose values did not differ, too,
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Figure 3.13: Control and SF-1∆IR did not show differences in glucose homeostasis when fed NCD.
(A) Average blood glucose levels in 20 week old control and SF-1∆IR males on NCD (n > 15 per
genotype). (B) Average serum insulin concentrations in 20 week old control and SF-1∆IR males on
NCD (n > 15 per genotype). (C) Intraperitoneal insulin tolerance test performed in 15 week old
control and SF-1∆IR males on NCD (n > 15 per genotype). (D) Intraperitoneal glucose tolerance
test performed in 16 week old control and SF-1∆IR males on NCD (n > 15 per genotype).
Displayed values are means ± S.E.M..
but insulin levels were significantly decreased in SF-1∆IR males, thereby indicating an in-
creased insulin sensitivity under conditions of HFD-feeding. This was further confirmed
by insulin and glucose tolerance tests. In both experiments, SF-1∆IR males showed an im-
proved glucose clearance from the bloodstream, further indicating an improved insulin
sensitivity in SF-1∆IR males under conditions of diet-induced obesity.
3.7 Increased PiP3 formation in the VMH promotes weight gain
As shown before, abrogation of insulin receptor mediated signaling in SF-1 neurons in
the VMH improves diet-induced obesity and glucose metabolism. To investigate whether
insulin-dependent signaling might be overactivated in conditions of diet-induced obesity
(DIO), PI3K signaling was investigated in control (SF-1lacZ) mice under conditions of obe-
sity. To this end, control SF-1lacZ and SF-1lacZ:∆IR fed HFD were fasted overnight, injected
with saline into the vena cava inferior and subsequently stained for PiP3. Under condi-
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Figure 3.14: SF-1∆IR show an improved glucose homeostasis under condtions of HFD-feeding.
(A) Average blood glucose levels in 20 week old control and SF-1∆IR males on HFD (n > 20 per
genotype). (B) Average serum insulin concentrations in 20 week old control and SF-1∆IR males
on HFD (n > 20 per genotype). (C) Intraperitoneal insulin tolerance test performed in 15 week old
control and SF-1∆IR males on HFD (n > 18 per genotype). (D) Intraperitoneal glucose tolerance
test performed in 16 week old control and SF-1∆IR males on HFD (n > 18 per genotype).
Displayed values are means ± S.E.M.; *, p ≤ 0.05.
tions of DIO, control mice display a higher PiP3 aggregation when compared to controls
under lean condition. When fed NCD, only 10 % of SF-1 neurons show high levels of
PiP3 accumulation (figure 3.6A). In HFD-fed controls, although they were fasted for 16
hours, the percentage of high immunoreactive SF-1 neurons increased to 40%. This ef-
fect was ameliorated in SF-1lacZ:∆IR mice (figure 3.15A). However, the percentage of SF-1
VMH neurons showing moderate PiP3 immunoreactivity was higher in HFD-exposed
SF-1lacZ:∆IR1 mice than in HFD-fed controls (figure 3.15A), indicating some residual diet-
induced activation of PI3K signaling in SF-1 VMH neurons even in the absence of insulin
receptor signaling. These experiments clearly indicate that HFD massively increases PI3K
activity in SF-1 VMH neurons and that this activation to substantial proportion depends
on insulin receptor signaling in these neurons.
To further functionally address the importance of diet-induced, insulin-dependent
overactivation of PI3K signaling in the VMH, it was aimed to mimic this effect through
genetic PI3K overactivation in vivo. Phosphatase and tensin homolog (PTEN) negatively
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Figure 3.15: Enhanced PI3K activation by HFD or PTEN deletion results in hyperphagia and in-
creased body weight.
(A) PiP3 levels after an overnight fast of control SF-1lacZ and SF-1lacZ:∆IR males exposed to HFD
for 10 weeks (n = 3 mice per genotype). (B) PiP3 levels after an overnight fast of control SF-1lacZ
and SF-1lacZ:∆PTEN males exposed to HFD for 10 weeks (n = 3 mice per genotype). (C) Body
weight curve of control (PTEN f l/ f l) and SF-1∆PTEN on either NCD or HFD for 17 weeks ( n >
10 per genotype and diet). (D) Average daily food intake of 12 week old control and SF-1∆PTEN
males on NCD.
Displayed values are means ± S.E.M.; *, p ≤ 0.05; **, p ≤ 0.01.
regulates PI3K signaling by dephosphorylating PiP3 to PiP2. Thus, deletion of PTEN
leads to accumulation of PiP3 and subsequent hyperactivation of the PI3K pathway (Mae-
hama & Dixon, 1998; Plum et al. , 2006). Therefore, mice were crossed as described in
Material and Methods. The ablation of PTEN yielded a greater number of SF-1 neurons
with moderate to high levels of PiP3 compared to that in control mice when the mice
were fed NCD (figure 3.15B). Thus, SF-1 VMH neuron-restricted PTEN ablation mimics
diet-induced overactivation of PI3K signaling in these neurons and therefore provides an
in vivo model of PI3K hyperactivation. This model was used to investigate the effect of
PI3K hyperactivation in the VMH on body weight and caloric intake. As shown in fig-
ure 3.15C (rectangles), SF-1∆PTEN males displayed a significantly increased body weight
when fed NCD, accompanied with an increased food intake (figure 3.15D). In contrast,
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HFD exposure of these mice results in a disappearance of the phenotype (figure 3.15C
triangles). Thus, hyperactivation of the PI3K pathway results in modest obesity under
NCD conditions, likely mimicking the effect of HFD-exposure at least partially.
To directly address the contribution of impaired PI3K activation in SF-1 neurons of
SF-1∆IR mice to the protection of these mice from the development of diet-induced obe-
sity, we generated mice lacking both insulin receptor and PTEN in SF-1 neurons (SF-
1∆IR:∆PTEN mice). Comparing body weight (figure 3.16A), total body fat content (figure
3.16B), epigonadal fat mass (figure 3.16C) and adipocyte size (figure 3.16D) in control
(PTEN f l/ f l :IR f l/ f l) and SF-1∆IR:∆PTEN mice exposed to HFD revealed that protection from
diet-induced weight gain and obesity in SF-1∆IR mice was abrogated by simultaneous ab-
lation of PTEN in these neurons.
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Figure 3.16: The additional deletion of PTEN in SF-1∆IR males normalizes body weight and adi-
posity under HFD conditions.
(A) Body weight curve of control (PTEN f l/ f l :IR f l/ f l) and SF-1∆IR:∆PTEN under HFD conditions (n
> 15 per genotype). (B) Average total body fat content measured by NMR in 20 week old control
and SF-1∆IR:∆PTEN males on HFD (n > 15 per genotype). (C) Average epigonadal fat pad weight
of 20 week old control and SF-1∆IR:∆PTEN males on HFD (n > 15 per genotype). (D) Average size
of adipocytes in the epigonadal white adipose tissue (WAT) of control and SF-1∆IR:∆PTEN males
on HFD at the age of 20 weeks (n = 3 mice per genotype).
Displayed values are means ± S.E.M..
Collectively, these experiments indicate that insulin-stimulated overactivation of PI3K
signaling in SF-1 VMH neurons is important in the development of HFD-induced obesity.
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3.8 Increased firing frequency of POMC neurons in SF-1∆IR
males under HFD conditions
To further investigate the molecular mechanism underlying the altered body weight reg-
ulation in SF-1∆IR males, we analyzed the expression of hypothalamic neuropeptides of
critical importance in the neuronal regulation of energy homeostasis (Asnicar et al. , 2001;
Clark et al. , 1985; Fan et al. , 1997; Gropp et al. , 2005; Li et al. , 2003; McMinn et al. ,
2000). Figure 3.17 indicates that the deficiency for the insulin receptor does not affect
the expression of neuropeptides involved in the regulation of the melanocortin system
(figure 3.17A). Furthermore, VMH specific neuropeptides, that are implicated in the reg-
ulation of energy homeostasis were also analyzed for their expression levels (Kernie et al.
, 2000; Kim et al. , 2012; Liao et al. , 2012). Figure 3.17B indicates that the expression
of both brain-derived neurotrophic factor (BDNF) and steroidogenic factor 1 (SF-1) was
unaltered between the genotypes.
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Figure 3.17: Quantitative real-time PCR on neuropeptides involved in the regulation of energy
homeostasis.
(A) Relative expression of pro-opiomelanocortin (POMC), agouti-related peptide (AgRP), cocaine
and amphetamine regulated transcript (CART) and neuropeptide Y (NPY) in 20 week old, HFD-
fed control and SF-1∆IR males at the age of 20 weeks. (B) Relative expression of steroidogenic
factor 1 (SF-1) and brain-derived neurotrophic factor (BDNF) in HFD-fed control and SF-1∆IR
males at the age of 20 weeks.
Displayed values are means ± S.E.M..
Thus, changes in the expression of the investigated gene products do not explain the
metabolic phenotype in mice lacking the insulin receptor in SF-1 neurons.
This raised the question how the leaner phenotype of SF-1∆IR mice was accomplished.
Another possible mechanism was published by Sternson and colleagues, who could
show that glutamatergic inputs from the VMH can alter the activity of POMC neurons
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in the ARC (Sternson et al. , 2005). To this end, electrophysiological recordings were per-
formed of POMC neurons, either in a control (POMCGFP) or in a SF-1∆IR background
(POMCGFP;SF-1∆IR) under HFD conditions. As shown in figure 3.18, POMC neurons
have an average firing rate of 1 Hz under conditions of HFD feeding. When POMC neu-
rons were recorded in the SF-1∆IR background, basal firing was increased to 3 Hz (figure
3.18B). Additionally, the number of silent POMC neurons was decreased from 50 % in
POMCGFP to 30 % in POMCGFP;SF-1∆IR mice (figure 3.18C). Figure 3.18A shows repre-
sentative recording traces of both genotypes.
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Figure 3.18: Electrophysiological recordings of POMC neurons of either control
(POMCGFP;IR f l/ f l) or SF-1∆IR (POMCGFP;SF-1∆IR) mice under HFD conditions.
(A) Representative recording traces of POMC neurons of control and SF-1∆IR mice under HFD
conditions. (B) Average firing frequency of POMC neurons of control and SF-1∆IR mice under
HFD conditions. (C) Percentage of silent and spontaneously firing SF-1 POMC neurons of control
and POMCGFP;SF-1∆IR mice under HFD conditions.
Displayed values are means ± S.E.M.; *, p ≤ 0.05.
Taken together, the lack of insulin receptors in the VMH does not influence the tran-
scriptional profile of the melanocortin system or other VMH specific neuropeptides, but
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rather influences the electrophysiological activity of the neighboring POMC neurons by
either direct or indirect synaptic inputs.
To test this hypothesis, inhibitory (IPSC) and excitatory post synaptic currents (EPSC)
were measured on POMC neurons in control (POMCGFP) or in POMCGFP;SF-1∆IR un-
der HFD conditions. As shown in figure 3.19, the frequency of IPSCs is significantly
decreased in SF-1∆IR mice, whereas the EPSCs tend to be higher but do not reach sig-
nificance. Additionally, the ratio of EPSC to IPSC was significantly increased in SF-1∆IR
animals, further pointing towards a role of insulin signaling in the VMH in the electro-
physiological regulation of POMC neuron activity. Thus, the increased firing activity of
POMC neurons in SF-1∆IR might be caused by either altered activity of neuronal inputs
on POMC neurons or by modifications in the synaptic organization in the ARC.
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Figure 3.19: Measurement of post synaptic currents (PSC) in HFD-fed POMCGFP and
POMCGFP;SF-1∆IR males.
(A) Average frequency of inhibitory post synaptic currents (IPSC) and excitatory post synaptic
currents (EPSC) on POMC neurons in HFD-fed POMCGFP and POMCGFP;SF-1∆IR males. (B) Ra-
tio of EPSC to IPSC on POMC neurons in HFD-fed POMCGFP and POMCGFP;SF-1∆IR males.
Displayed values are means ± S.E.M.; *, p ≤ 0.05; **, p ≤ 0.01.
To test this, synaptic inputs on POMC neurons of control and SF-1∆IR animals were ex-
amined by electron-microscopy as described by Pinto and colleagues (Pinto et al. , 2004).
Inhibitory (GABAergic) and excitatory (glutamatergic) synapses differ in their morphol-
ogy, when observed by electron microscopy. GABAergic synapses show a symmetric
morphology, whereas glutamatergic synapses display a rather asymmetric morphology.
To confirm this findings, synapses are additionally stained for GABA and glutamate. As
shown in figure 3.20A and B, no alterations could be observed between control and SF-
1∆IR animals under conditions of NCD-feeding. When those mice were fed HFD, the
number of synapses changed dramatically. As shown before (Horvath et al. (2010)), the
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number of inhibitory synapses on POMC neurons increased massively upon HFD feed-
ing (figure 3.20A and C), whereas only slight changes were observable in the number
of excitatory inputs. Accordingly, the ratio of excitatory to inhibitory inputs was signif-
icantly increased in SF-1∆IR males on HFD when compared to their littermate controls
(figure 3.20D).
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Figure 3.20: Number of inhibitory and excitatory synapses on POMC neurons per 100 µm
perikarya of control and SF-1∆IR males under NCD and HFD conditions.
(A) Average number of inhibitory and excitatory synapses on POMC neurons per 100 µm
perikarya in control and SF-1∆IR males on NCD. (B) Ratio of excitatory to inhibitory synapses
on POMC neurons in control and SF-1∆IR males on NCD. (C) Average number of inhibitory and
excitatory synapses on POMC neurons per 100 µm perikarya in HFD-fed control and SF-1∆IR
males. (D) Ratio of excitatory to inhibitory synapses on POMC neurons in HFD-fed control and
SF-1∆IR males.
Displayed values are means ± S.E.M.; ***, p ≤ 0.001.
Taken together, POMC neurons are inhibited in their activity upon HFD-feeding, which
is ameliorated in SF-1∆IR males (figure 3.18). As shown by post synaptic current measure-
ments, this is likely caused by alterations in the type post-synaptic currents on POMC
neurons (figure 3.19) and could be further confirmed by electron-microscopical examina-
tion of synaptic inputs (figure 3.20).
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3.9 Counterregulatory response to hypoglycemia
To elucidate a role of insulin signaling in SF-1 neurons in the counter-regulatory re-
sponse to hypoglycemia (CRR), control and SF-1∆IR females and males were operated
as described in Material and Methods. After 7 days of recovery, mice were exposed to a
hypoglycemic-hyperinsulinemic clamp (figure 3.21).
-20 -10 0 10 20 30 40 50 60 70 80 90 100 110 120 
Blood 
PBS 3% mouse 
plasma 
Insulin 
20% glucose as needed 
Time [min] 
Figure 3.21: Protocol for the hypoglycemic-hyperinsulinemic clamp studies.
Mice were adjusted to a blood glucose level of ∼50 mg/dL by a constant infusion of insulin and
an adapted infusion of 20% glucose solution. Blood samples were taken before insulin is infused
(at -20) and in the steady state.
Hypoglycemic-hyperinsulinemic clamp studies were conducted on female (figure 3.22)
and male (figure 3.23) control and SF-1∆IR mice at the age of 12 to 14 weeks. During
the clamp, blood glucose levels were monitored every 10 minutes. When blood glucose
values reached a threshold of 70 mg/dL, glucose infusion was started to prevent a hy-
poglycemic shock. The glucose infusion rate was adapted to reach a steady state at least
90 min after initiation of insulin infusion. As shown in figure 3.22A, both controls and
SF-1∆IR females reached a steady-state at least after 90 min of insulin infusion. The glu-
cose infusion rate (GIR), as depicted in figure 3.22B, was significantly higher in SF-1∆IR
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females when compared to controls, thus indicating in impaired counter-regulatory re-
sponse to hypoglycemia (CRR). Thus, plasma samples that were taken during the clamp
were analyzed for circulating epinephrine, norepinephrine, corticosterone and glucagon
concentrations. Figure 3.22C and D indicate no differences between SF-1∆IR females and
controls, neither in epinephrine, norepinephrine, corticosterone nor circulating glucagon
levels. Although glucagon levels seem to be slightly decreased in SF-1∆IR females in the
steady-state, it did not reach statistical significance.
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Figure 3.22: Hypoglycemic-hyperinsulinemic clamp studies of 12 to 14 week old female control
and SF-1∆IR animals.
(A) Average blood glucose values during the clamp study of control and SF-1∆IR females. (n
> 9) (B) Average glucose infusion rate of control and SF-1∆IR females. (n > 9) (C) Enzyme
immunoassay of basal and steady state plasma samples from control and SF-1∆IR females for
epinephrine and norepinephrine. (n > 9) (D) Enzyme immunoassay and radioimmuno assay of
basal and steady state plasma samples from control and SF-1∆IR females for corticosterone and
for glucagon. (n > 9).
Displayed values are means ± S.E.M.; *, p ≤ 0.05.
Due to the fact that significant differences in body weight were only observed in male
animals, hypoglycemic-hyperinsulinemic clamps were also conducted in male control
and SF-1∆IR males on NCD. Also in males, a steady-state was reached by constant in-
fusion of insulin and a variable infusion of glucose (figure 3.23A). Whereas female mice
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showed an increased GIR during the steady-state of the clamp, male mice also tend to
have an increased GIR, but did not reach significance (figure 3.23B).
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Figure 3.23: Hypoglycemic-hyperinsulinemic clamp studies of 12 to 14 week old male control and
SF-1∆IR animals.
(A) Average blood glucose values during the clamp study of control and SF-1∆IR males. (B) Av-
erage glucose infusion rate of control and SF-1∆IR males.
Displayed values are means ± S.E.M..
Thus, SF-1∆IR females require an increased GIR to reach the steady state, but the rea-
son for the increased GIR needs to be further elucidated. Male SF-1∆IR mice also have the
tendency to need an increased GIR, but more animals have to be analyzed to verify these
findings.
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Over the last decades, growing evidence suggested that obesity and insulin resistance,
with T2DM as a consequence, are strongly associated and obesity is now considered as
the pandemic of the 21st century (Mokdad et al. , 2003; WHO, 2012). The increases in the
incidence for obesity and insulin resistance worldwide create a mandatory necessity for
the understanding of neuronal and peripheral mechanisms underlying the development
of obesity and its co-morbidities. Furthermore, evidence from the last years suggest that
especially maternal obesity is able to contribute massively to the further propagation of
obesity in western countries by epigenetical imprinting (Heerwagen et al. , 2010).
Although an overwhelming amount of studies, dealing with obesity, have been pub-
lished over the last decades, the underlying molecular mechanisms still remain to be
elucidated. It is still not fully understood how the peripheral hormones leptin and in-
sulin control the regulation of energy homeostasis in the brain and a lot of target brain
areas of these hormones still have to be investigated. Whereas the hypothalamus has
been identified as a pivotal brain region in the control of energy homeostasis more than
70 years ago (Hetherington & Ranson, 1940), the projection sites and further connections
to higher brain regions have not yet been accurately defined. One of the best character-
ized circuits in the hypothalamus and definitely a major target for insulin’s and leptin’s
action is the melanocortin system in the ARC, including the first order neuronal pop-
ulations of POMC and AgRP expressing neurons. As shown by several knockout and
ablation studies in rodents, the melanocortin system in the ARC is not the only circuit in
the CNS controlling energy balance. For example, deletion of the IR in POMC neurons
does not influence body weight, whereas either LepR deficiency or even the specific abla-
tion of POMC neurons results in modest obesity (Cohen et al. , 2001; Cowley et al. , 2001;
Gropp et al. , 2005; Könner et al. , 2007; Luquet et al. , 2005). Furthermore, LepRs and IRs
are widely expressed in the brain, indicating a role for leptin and insulin signaling in the
regulation of energy homeostasis in other brain areas as well (Havrankova et al. , 1978a;
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Mercer et al. , 1996b; Oomura & Kita, 1981). Thus, the exact mechanisms downstream of
the melanocortin system is still a subject of research.
Already before the discovery of the melanocortin circuits in the ARC, the neighboring
VMH was considered to be the main satiety center in the brain (Gold, 1973; Marshall &
Mayer, 1956). Initially identified by lesion experiments and electrical stimulations, the
signals that control VMH neuron activity and output have been further defined by new
methods and techniques, such as the cre-loxP system. By the abrogation of leptin signal-
ing in SF-1 neurons, leptin has been identified as key mediator in the VMH in the control
of energy homeostasis. Leptin is able to directly stimulate firing activity in VMH SF-1
neurons, and lack of LepRs results in modest obesity, suprisingly to a similar extent as
POMC-specific LepR deficiency (Dhillon et al. , 2006). Furthermore, the deletion of LepRs
in both POMC and SF-1 neurons has additive effects, resulting in severe obesity. Notably,
upon HFD-exposure LepR deficiency in SF1 neurons aggravates the diet-induced weight
gain, thus proposing a role for SF-1 neurons to compensate for the diet-induced leptin
resistance in POMC neurons (Dhillon et al. , 2006; Munzberg et al. , 2004). In contrast,
the lack of leptin’s negative regulator, SOCS-3, improves glucose homeostasis and leptin
signaling in the VMH, but has no effect on body weight or adiposity (Zhang et al. , 2008a).
Further evidence suggests that the VMH specific neurotrophin brain-derived neu-
rotrophic factor (BDNF) is involved in the control of energy homeostasis. BDNF is ex-
pressed in the hindbrain and some hypothalamic nuclei, but most abundantly in the
VMH (Conner et al. , 1997; Wang et al. , 2010). When BDNF is infused into the brain
of rats, it reduces the food intake and accordingly, BDNF mRNA levels are reduced upon
fasting (Lapchak & Hefti, 1992; Tran et al. , 2006; Xu et al. , 2003). Furthermore, the deletion
of BDNF in the VMH and DMH results in hyperphagia and consequently obesity (Unger
et al. , 2007). However, how the anorectic effects of BDNF are transmitted is unclear.
The effect of insulin in the CNS is still under investigation, although its role in the
periphery and certain brain areas has been intensively studied. Initially identified by
Woods and colleagues as an adiposity signal from the periphery (Woods et al. , 1979),
insulin’s role in the CNS mediated control of energy homeostasis has been further clari-
fied over the last years. The neuron-specific insulin receptor knockout (NIRKO) mouse
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develops modest obesity, clearly indicating an important role for insulin in the CNS in
the control of energy homeostasis (Brüning et al. , 2000). Further studies revealed that
central insulin is also implicated in the control of lipid metabolism and hepatic gluco-
neogenesis. When insulin signaling is abolished in the brain, mice exhibit unrestrained
lipolysis in the adipose tissue and consequently increased levels of fatty acids in the cir-
culation (Koch et al. , 2008; Scherer et al. , 2011). As shown by Könner and colleagues,
insulin regulates hepatic glucose production via AgRP neurons (Könner et al. , 2007). In
POMC neurons, insulin activates, together with leptin, the transcription of POMC in a
PDK1 dependent manner (Belgardt et al. , 2008). Furthermore, over-activation of insulin
signaling in POMC neurons by the deletion of PTEN likewise results in modest obesity
(Plum et al. , 2006).
Although the VMH has been investigated for many years, the VMH derived signals
are not yet fully understood. In addition to leptin’s role as a stimulator of SF-1 VMH
neuron firing activity and BDNF as a satiety signal within the VMH, glutamatergic pro-
jections from the VMH are necessary to maintain a normal body weight. When glutamate
is prevented to be transported into secretory vesicles, disturbances in energy balance are
observed (Tong et al. , 2007a). Moreover, glutamatergic inputs from the VMH to POMC
neurons could be observed in uncaging experiments, further supporting the importance
of glutamate release from the VMH in the maintenance of body weight (Sternson et al.
, 2005). However, the exact mechanisms that regulate SF-1 VMH neuron activity and
transcriptional profile have to be elucidated.
Although both insulin signaling and SF-1 neurons are implicated in the CNS-mediated
control of energy homeostasis and insulin receptors are highly expressed in the VMH
(Oomura & Kita, 1981), insulin’s role in SF-1 expressing neurons in the VMH has not
been studied so far.
4.1 Successful generation of SF-1 cell specific insulin receptor
knockout mice
To get insights into insulin’s role in VMH SF-1 neurons, Cre mediated recombination was
used to delete specifically exon 4 of the insulin receptor gene in SF-1 expressing cells. Even
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though SF-1 is reported to be expressed in the pituitary gland, adrenal gland, spleen,
testis and ovaries, no alterations in the protein level of the IR were observed. To exclude
any defects in the hypothalmus-pituitary-gonadal (HPG) axis by either IR deficiency in
the hypothalamus, pituitary gland or the gonads, breeding efficiency was analyzed. No
alterations could be observed in average litter frequency or average litter size. Further-
more, the expression of hormones, regulating the HPG axis in the pituitary gland, was
unchanged and free triiodthyronin (T3) levels in the serum of control and SF-1∆IR males
were unaltered. Thus, the integrity of the HPG axis and proper gonadal function was
assured. Whereas the deletion of the SF-1 gene results in developmental defects in the
VMH and subsequently in a complete lack of this hypothalamic nuclei, no structural or
morphological abnormalities were visible. Moreover, in situ hybridization against exon 4
of the insulin receptor mRNA showed a reduction of 50 %, whereas no significant reduc-
tion was seen in the neighboring DMH. This reduction was congruent with the observed
expression pattern of the SF-1 Cre, as only about 50 % of the neurons in the VMH were
Cre positive (personal observation). As shown by other researchers, SF-1 is not expressed
in every neuron in the VMH, thus in line with the observed reduction in insulin receptor
mRNA (Dhillon et al. , 2006; Kim et al. , 2009).
To confirm the functionality of the IR deletion, VMH sections of saline injected and
insulin stimulated control and SF-1∆IR animals were analyzed for PiP3 formation. By
the quantification of insulin stimulated PiP3 accumulation, the efficient Cre-mediated
recombination of the insulin receptor gene was verified. In control reporter animals, an
increase in PiP3 formation upon insulin stimulation could be observed, indicating a cell-
autonomous activation of SF-1 neurons in the VMH by insulin. This effect was com-
pletely absent in SF-1∆IR reporter animals, as no increase in PiP3 formation could be ob-
served. Notably, a subset of ∼20 % of SF-1 neurons revealed low PiP3 formation despite
a 20 min stimulation with insulin, possibly representing SF-1 neurons that do not ex-
press the IR. Furthermore, differences in the ability of insulin to stimulate PiP3 formation
were observed. SF-1 neurons in the medio-basal part of the VMH showed higher PiP3
levels than SF-1 neurons in the ventro-lateral area, both after 10 and 20 min of insulin
stimulation. This can be caused either by a different responsiveness to insulin through
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higher insulin receptor expression or by a different accessibility of insulin to the brain re-
gions. Insulin is transported across the blood-brain barrier (BBB) by a saturable transport
mechanism (Banks et al. , 1997), but the further distribution in the brain via diffusion or
ventricular cerebro-spinal fluid has not been studied so far.
Taken together, the majority of SF-1 neurons in the VMH are insulin responsive and
insulin receptors in these neurons were efficiently deleted, although a subpopulation of
VMH SF-1 neurons is not responsive to insulin. Thus, the mechanisms of insulin’s distri-
bution and the expression pattern of insulin receptors has to be further studied.
4.2 Insulin electrically inhibits SF-1 neurons via KATP channels
To examine the effect of insulin on electrophysiological properties of SF-1 neurons, patch-
clamp recordings of identified SF-1 neurons were performed. In control SF-1GFP neurons,
insulin was able to hyperpolarize SF-1 neurons and thereby reduce their firing rate. This
inhibition of firing activity was reversible when tolbutamide, a selective ATP-dependent
potassium (KATP) channel blocker, was added to the bath, thus indicating that the hyper-
polarization is mediated by KATP channels. Importantly, only 40 % of the recorded SF-1
neurons were responsive to insulin, and most of them were clustered in the medio-basal
part of the VMH, recapitulating the observations acquired by insulin stimulated PiP3
formation experiments. Of note, insulin stimulated depolarization could be observed in
only 1 out of 14 control SF-1 neuron.
When SF-1GFP:∆IR neurons were recorded, no effect of insulin could be observed. In-
sulin application did not result in obvious effects on membrane potential or firing rate,
thus confirming the efficient Cre-mediated deletion of the IR. Furthermore, basal prop-
erties of SF-1GFP and SF-1GFP:∆IR, such as whole-cell capacitance and input resistance,
were indistinguishable between both genotypes, thus indicating no functional defect in
SF-1 neurons upon IR deficiency. Moreover, 2 out of 12 neurons from SF-1GFP:∆IR animals
depolarized after insulin application, thus indicating an unspecific effect, also in the one
depolarized control SF-1 neuron.
To investigate the interplay of leptin and insulin in SF-1 neurons, either single or se-
quential application during electrophysiological recordings were performed. The single
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application revealed that a subpopulation of SF-1 neurons are both leptin and insulin
sensitive, but the majority of the recorded neurons did not respond to either of the ap-
plications (22 out of 70 responded to leptin and 5 out of 18 to insulin). When leptin and
insulin were sequentially applied, none of the examined neurons (n = 39) responded to
both leptin and insulin.
Thus, insulin is able to silence a subpopulation of SF-1 neurons in the VMH, mainly in
the medio-basal part, via KATP channels. Furthermore, SF-1 neurons obviously represent
a heterogenic population of VMH neurons, that likely segregate into leptin and insulin
responsive neurons, which has to be further investigated. To this end, mice will be ana-
lyzed that lack the IR and/or the LepR in VMH SF-1 neurons to unravel if the lack of IRs
can partially compensate the obesity-promoting effect of LepR deficiency (Dhillon et al. ,
2006).
4.3 Attenuation of obesity upon SF-1 specific IR deficiency
Earlier studies, e.g. by Woods and Porte, indicated a role for insulin in the brain as a adi-
posity and satiety signal (Woods et al. , 1979). In line with these observations, mice lacking
the insulin receptor in the whole brain are moderately obese (Brüning et al. , 2000). But
as mentioned earlier, the exact neuronal population of insulin’s anorectic action remains
unclear.
As shown by Könner and colleagues, insulin receptor deficiency in POMC and AgRP
neurons does not alter body weight or adiposity (Könner et al. , 2007). Thus the VMH rep-
resents a possible target for the anorectic effect of insulin. But under NCD conditions, no
alterations in body weight, glucose homeostasis or adiposity could be observed. In con-
trast, when control and SF-1∆IR mice were fed a HFD, SF-1∆IR males were significantly
lighter and until 14 weeks of age completely protected against the diet-induced weight
gain. Females had the same tendency towards reduced body weight and adiposity, but
this never reached significance due to high deviations within the genotypes (personal
observation). The decreased body weight was caused by a decreased fat mass, as the
reduction in body weight reflects the reduction in fat mass. On average both genotypes
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had a lean mass of ∼24 g, but control animals had ∼21 g fat mass in contrast to ∼17 g fat
mass in SF-1∆IR males.
The decreased adiposity was also reflected by the serum leptin levels. Whereas no
differences could be observed under NCD conditions, SF-1∆IR males had significantly
lower circulating leptin levels when exposed to HFD, both at 8 and 20 weeks of age, and
reduced mean adipocyte size, which has been shown to influence leptin secretion (Skurk
et al. , 2007). Thus, leptin sensitivity seems to be increased in SF-1∆IR males on HFD, as it
is reported in lean vs. obese subjects (Heymsfield et al. , 1999).
In order to obtain further insights into the underlying mechanism of the reduced adi-
posity upon HFD-feeding in SF-1∆IR males, food intake and energy expenditure were
measured in 6 to 7 and 12 to 13 week old males. In younger control and SF-1∆IR males,
that did not differ in body weight, both food intake and energy expenditure were not
significantly changed. Also in older (12 to 13 week old) animals, energy expenditure
was unchanged, whereas the absolute food intake was significantly decreased in SF-1∆IR
males. However, when normalized to body weight, no changes could be observed be-
tween both genotypes. This indicates that the reduction in food intake might also be a
secondary effect of the reduced adiposity in SF-1∆IR animals.
To test if young SF-1∆IR males already show differences in leptin’s ability to reduce
food intake, 8 week old mice were injected icv with leptin and food intake was moni-
tored. This revealed a significantly improved leptin sensitivity in young SF-1∆IR males,
although the body weight did not differ from controls at this age.
Taken together, insulin receptor deficiency in VMH SF-1 neurons partially protects
against diet-induced weight gain by improving leptin’s ability to decrease food intake
before obvious effects on body weight could be monitored. This effect did only reach
statistical significance in male animals, not in females. A possible reason for this effect is
the effect of estrogen. As shown by Gao and colleagues, estrogen is able to reduce food
intake by changing the synaptic input of the ARC melanocortin system, independent of
leptin (Gao et al. , 2007). Thus, the differences observed in male animals in leptin’s ability
to reduce food intake might be overruled by different levels of circulating estrogen during
the cycle and thus leading to the observed high deviations within the genotypes.
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4.4 Improved glucose metabolism in SF-1∆IR males on HFD
Under NCD conditions, control and SF-1∆IR animals did not show any alterations in the
examined metabolic parameters. The same holds true for glucose tolerance and insulin
sensitivity, assessed by glucose and insulin tolerance tests. Though, SF-1∆IR males on
HFD showed increased glucose tolerance and improved insulin sensitivity. As these ex-
periments were performed at 15 and 16 weeks of age, both genotypes displayed already
significant differences in body weight and presumably also adiposity (not measured at
that age). As there is no direct connection between VMH neurons and peripheral glucose
metabolism known so far, the improved glucose clearance in both experiments is most
likely a secondary effect of the reduced adiposity. This finding is supported by the fact
that obesity and insulin resistance are intimately linked conditions.
4.5 PiP3 formation in SF-1 VMH neurons promotes obesity
As VMH SF-1 neurons are insulin responsive under NCD conditions, shown by PiP3 for-
mation upon insulin stimulation, the effect of HFD-feeding on insulin responsiveness in
VMH SF-1 neurons was investigated. By the analysis of PiP3 levels in HFD fed control
(SF-1lacZ) and knockout reporter (SF-1lacZ:∆IR) animals, we could show that HFD-feeding
induces PiP3 accumulation in the VMH even after 16 hours of fasting. Although it is
known that HFD-feeding leads to hyperinsulinemia in the periphery, it was so far un-
clear if the brain and, in particular, the VMH are affected by increased circulating insulin.
Whereas neurons in the ARC, such as POMC and AgRP neurons, are considered to be-
come insulin resistant upon HFD feeding (Clegg et al. , 2011; Ernst et al. , 2009; Mayer &
Belsham, 2010), we could show that neurons in the VMH remain insulin sensitive. Fur-
thermore, this enhanced insulin signaling in SF-1 neurons, compared to ARC neurons,
probably contributes to the diet-induced weight gain, as insulin receptor deficiency in
SF-1 neurons partially protects against diet-induced obesity and PiP3 formation is signif-
icantly reduced in SF-1∆IR males on HFD.
To further test this hypothesis, mice were generated lacking the negative regulator
of PI3K signaling, PTEN (SF-1∆PTEN). The efficient ablation of PTEN in VMH SF-1 neu-
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rons could be shown by increased PiP3 formation under unstimulated, saline injected
NCD conditions after a 16 h fasting period. SF-1∆PTEN mice showed an increased body
weight upon NCD feeding, whereas no alterations could be observed between control
(PTEN f l/ f l) and SF-1∆PTEN males when fed a HFD. The elevated body weight on NCD
was caused by an increase in food intake.
Importantly, the beneficial effects of insulin receptor deficiency in SF-1 neurons upon
HFD feeding was completely normalized when PTEN was additionally deleted. This is
likely caused by other stimuli of the PI3K pathway, such as leptin or insulin like growth
factor 1 (IGF1) receptor signaling. Both have been shown to either activate the PI3K path-
way, either by leptin-stimulated phosphorylation of insulin receptor substrates by JAK or
by direct binding of insulin to the insulin-like growth factor 1 receptor (IGF1-R) (Cohen
et al. , 1996; Hill et al. , 2008; Latres et al. , 2005; Pomerance et al. , 1995). When PTEN
is absent in SF-1 neurons, both stimuli can slightly activate PI3K, despite IR deficiency,
which leads to an accumulation of PiP3, as it cannot be de-phosphorylated to PiP2.
These experiments further support the findings that PiP3 formation in VMH SF-1 neu-
rons promotes weight gain, shown by both diet-induced but also genetically induced
obesity. As SF-1∆PTEN mice on HFD do not display any differences in body weight, we
hypothesize that the deficiency for PTEN mimics the effect of HFD feeding in VMH SF-1
neurons.
Another noteworthy finding of this study is the fact that VMH SF-1 neurons remain in-
sulin sensitive, in contrast to other neuronal populations. This phenomenon of selective
insulin resistance is already known from peripheral organs. In the liver of obese mice,
insulin fails to inhibit hepatic glucose production via the PI3K pathway and FOXO1, but
continues to promote lipid synthesis via the SREBP-1c pathway (Biddinger et al. , 2008).
Interestingly, selective insulin resistance for different pathways develops in the liver, al-
though hepatocytes represent a quite homogenous population of cells. In contrast to
the liver, the brain consists of thousands of specialized neuronal subpopulations, each
with specialized gene expression profiles and connections. Hence, selective insulin resis-
tance for different pathways is also known for the CNS. Insulin is still able to activate the
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MAPK pathway, but fails to induce signaling via the PI3K pathway in obese Zucker rats
(Carvalheira et al. , 2003).
In this study it was shown for the first time that selective insulin resistance also affects
the same signaling pathway in distinct neuronal populations. Exposure to HFD leads
to the development of insulin resistance in POMC neurons, associated with a decreased
POMC expression and the inability of insulin to decrease food intake (Clegg et al. , 2011;
Mayer & Belsham, 2010). In contrast to ARC neurons, VMH SF-1 neurons remain in-
sulin sensitive, at least up to 5 weeks of HFD-feeding. It is possible that the prolonged
exposure to HFD leads to a complete neuronal and peripheral insulin resistance, which
would explain the loss of protection against diet-induced weight gain after 12 weeks of
HFD feeding. From this age on, control and SF-1∆IR males show a similar weight gain,
although SF-1∆IR males are still significantly lighter. One important factor for the devel-
opment of insulin and leptin resistance are elevated levels of circulating saturated free
fatty acids (sFFA), like palmitate, as they are able to induce inhibitory signaling via the c-
Jun n-terminal kinase (JNK) pathway and ER stress (Cintra et al. , 2012; Kleinridders et al.
, 2009; Mayer & Belsham, 2010). POMC and AgRP neurons in the ARC are directly ex-
posed to metabolites from the blood circulation due to their proximity to the blood-brain
barrier (BBB). As VMH SF-1 neurons are located in a greater distance from the BBB, they
might be exposed to lower levels of circulating insulin, FFA and inflammatory cytokines
from the periphery and thus retain their insulin sensitivity.
Taken together, insulin signaling in SF-1 VMH neurons promotes obesity in a PI3K
dependent manner. Furthermore, VMH SF-1 neurons retain their insulin responsiveness
under HFD conditions longer than ARC neurons and thus further promote the develop-
ment of obesity, but the phenomenon of selective insulin resistance and the underlying
molecular mechanisms have to be further investigated.
4.6 Unaltered expression of hypothalamic neuropeptides, but
increased activity of POMC neurons
Leptin exerts several effects in the hypothalamus to reduce food intake and increase en-
ergy expenditure. Besides a lot of yet unidentified targets, leptin has been shown to
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increase the expression of POMC and to inhibit the expression of its antagonist, AgRP
(Mizuno et al. , 1998; Schwartz et al. , 1997). Additionally, NPY and CART are also reg-
ulated by leptin (Kristensen et al. , 1998; Schwartz et al. , 1998). Thus, the expression
of neuropeptides was analyzed by quantitative real-time PCR. None of the examined
neuropeptides showed alterations in mRNA levels, nor did BDNF, which is strongly as-
sociated with the control of energy homeostasis in the VMH (Caruso et al. , 2012; Jo, 2012;
Kernie et al. , 2000; Liao et al. , 2012; Unger et al. , 2007; Wang et al. , 2010). Thus, changes
in the expression level of neuropeptides are not the reason for the reduced adiposity. Re-
cent publications also indicate a role for FOXO1 in VMH SF-1 neurons in the regulation
of energy homeostasis by modulating energy expenditure via the sympathetic nervous
system and that FOXO1 regulates the expression of SF-1 (Kim et al. , 2012). However,
expression of SF-1 mRNA remained unaltered. Furthermore, when the PiP3 dependent
downstream kinase (PDK1) is deleted, no effect is observed neither on NCD nor on HFD
(personal communication with Bengt F. Belgardt). Due to the fact that PDK1 phosphory-
lates and thereby activates AKT, that mediates insulin effects on the transcriptional level,
alterations in gene expression can be excluded as a reason for the observed phenotype.
As we have previously demonstrated, leptin’s ability to reduce food intake is im-
proved in SF-1∆IR males on HFD. Therefore we analyzed further targets of leptin’s action
in the hypothalamus. Leptin is able to modulate POMC neurons activity by non-specific
cation channels and thereby regulates the release of POMC cleavage product, α-MSH,
into the target areas of POMC neurons. We could show that POMC neurons in SF-1∆IR
animals have an increased spontaneous firing activity as compared to POMC neurons
in control (IR f l/ f l) animals under HFD conditions. Furthermore, the number of silent
POMC neurons is largely reduced in HFD-fed SF-1∆IR animals compared to their control
littermates.
Thus, the decreased body weight in SF-1∆IR males upon HFD-feeding is likely to be
caused by an enhanced basal firing rate of POMC neurons and thereby an increased re-
lease of α-MSH into the target areas, leading to a reduced food intake.
However, it is still unclear how SF-1 neurons contribute to this effect, and especially
how insulin signaling in these neurons contributes to the firing rate of POMC neurons.
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We could show in patch-clamp recordings of control SF-1 neurons that insulin signifi-
cantly hyperpolarizes SF-1 neurons and thereby reduces their firing rate. Most of the
neurons that display the hyperpolarization-response to insulin are located in the medio-
basal part of the VMH, thus in the direct proximity of the ARC, where POMC and AgRP
neurons are located. Thus, we hypothesize that SF-1 neurons send excitatory synapses
from the medio-basal VMH to POMC neurons in the ARC. This hypothesis is supported
by two publications: (I) Tong and colleagues were able to show that glutamate release
from SF-1 neurons is necessary for the regulation of body weight under HFD conditions
(Tong et al. , 2007a). When glutamate packaging into synaptic vesicles was prevented
by the deletion of the glutamate transporter Vglut2 in SF-1 neurons, mice became even
more obese when fed a HFD. Notably, this increased body weight also resulted from an
increase in fat mass, whereas lean mass was unaltered. Thus, glutamate release from SF-1
neurons is important for body weight and fat mass regulation, especially under HFD con-
ditions. (II) Further support arises from the publication of Sternson and colleagues. They
topographically mapped connections between the ARC and the VMH by laser scanning
photostimulation, where glutamate is uncaged at several distinct locations by simultane-
ously recording possible target neurons. By these experiments they were able to create
heat-maps of GABAergic and glutamatergic projections to POMC, NPY and unidentified
neurons in the ARC (Sternson et al. , 2005).
Inhibitory inputs on POMC neurons mainly arise from projections within the ARC,
presumably NPY/AgRP neurons (Sternson et al. , 2005). This implicates that the changes
in the inhibitory input, observed in post-synaptic current measurements and also in the
electron-microscopy, are rather a secondary effect of the reduced adiposity. As Pinto and
colleagues could show, leptin is able to re-organize the synaptic input of POMC neu-
rons (Pinto et al. , 2004). In states of leptin resistance, either genetically or diet-induced,
the number and frequency of inhibitory inputs is massively increased on POMC neu-
rons. Due to the fact that both post-synaptic current measurements as well as electron-
microscopy were performed in mice that already differed in body weight and adiposity,
leptin resistance was more pronounced in control than SF-1∆IR animals, thus explain-
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ing the observed differences in IPSC frequency and number of GABAergic synapses on
POMC neurons.
On the other hand, excitatory glutamatergic input on POMC neurons mainly arises
from an area in the "medial VMH" (or medio-basal VMH, mVMH) (Sternson et al. , 2005),
the area where most of the PiP3 formation was observed and the area with the highest
density of insulin-responsive SF-1 neurons. This indicates that the glutamatergic neurons
in the mVMH are inhibited in their ability to elicit action potentials by the HFD-induced
hyperinsulinemia and thus in their ability to release glutamate on POMC neurons. This
results in decreased α-MSH release from POMC-nerve terminals onto MC4R expressing
second-order neurons and consequently in increased food intake. This insulin-induced
hyperpolarization is absent SF-1∆IR animals, resulting in an increased excitatory tone on
POMC neurons. This further enables the occurrence of action potentials in POMC neu-
rons (either leptin induced, but also in states of leptin resistance), resulting in an elevated
release of α-MSH and finally reduced food intake via MC4R signaling. Although the dif-
ferences in excitatory input are not as obvious as the changes in inhibitory input, this
might be again influenced by the age of the analyzed mice. Both, electron-microscopy
and post-synaptic current measurements were performed in animals with significant dif-
ferences in body weight and adiposity, indicating a different degree of leptin resistance
between the genotypes and thus a more prominent change in the inhibitory input re-
organization. And although the changes in excitatory inputs did not reach statistical sig-
nificance in both experiments, mean values of the excitatory input were higher in SF-1∆IR
animals on HFD compared to controls. Further analysis of synaptic input organization
on POMC neurons in younger animals is needed to confirm this hypothesis.
Finally, the excitatory projections from the mVMH are reduced when mice were fasted
and this reduction is not reversed by additional treatment with leptin (Sternson et al. ,
2005). This indicates that glutamatergic neurons in the mVMH are likely to be glucose-
excited neurons, that induce satiety upon elevated glucose concentrations. As shown
by Cotero and colleagues, insulin is able to reduce the sensitivity to glucose in glucose-
excited VMH neurons via KATP channels, which is completely in line with our observa-
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tions (Cotero & Routh, 2009). The fact that leptin is not able to reverse the effect of fasting
indicates that leptin and insulin responsive neurons are indeed segregating populations.
Taken together, results from this study indicate that VMH SF-1 neurons send gluta-
matergic projections to POMC neurons to trigger α-MSH release in the PVN. Under HFD
conditions, hyperinsulinemia impairs the release of glutamate to POMC neurons, which
further decreases activity of POMC neurons and leads to increased weight gain (figure
4.1). Although this model is supported by two other publications, further studies about
the synaptic connections of VMH SF-1 neurons will be performed by using iZ/WAP mice
to unravel projection targets of SF-1 neurons (Louis et al. , 2010).
Figure 4.1: Model of insulin’s effect in VMH SF-1 neurons. Image taken from Könner & Bruning
(2012).
In lean animals, VMH SF-1 neurons provide glutamatergic synapses on POMC neurons to trig-
ger the release of α-MSH from POMC neurons in the ARC. Obesity associated hyperinsulinemia
impairs the activity of VMH SF-1 neurons, further decreasing the activity of POMC neurons. Fur-
thermore, insulin resistance in POMC neurons upon HFD feeding impairs the transcription of
POMC, whereas VMH SF-1 neurons remain insulin sensitive.
4.7 Impaired counter-regulatory response to hypoglycemia in
SF-1∆IR animals
The aforementioned results raise the question if insulin signaling in VMH SF-1 neurons
also contributes any beneficial effects. As shown by Fisher and colleagues, insulin in
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the CNS is mandatory to induce the counter-regulatory response to hypoglycemia (CRR)
(Fisher et al. , 2005). Furthermore, Tong and colleagues could show that glutamate in
SF-1 neurons plays a pivotal role in the induction of CRR by innervation of the adrenal
gland and the pancreas via the vagus nerve (Tong et al. , 2007a). Recent results by Diggs-
Andrews and colleagues could show that insulin signaling in the VMH is necessary to
drive the expression of the insulin-dependent glucose transporter GLUT4 in these neu-
rons, and that GLUT4 is mandatory for the glucose sensing properties of VMH neurons
(Diggs-Andrews et al. , 2010).
Thus we hypothesized that the lack of insulin signaling in VMH SF-1 neurons may be
responsible for the defective CRR observed in NIRKO mice. To this end, hypoglycemic-
hyperinsulinemic clamp studies were performed in control and SF-1∆IR males and fe-
males.
On the level of the glucose infusion rate, we were able to identify SF-1 neurons as the
responsible neuronal population in the VMH for the induction of the CRR in females,
as female SF-1∆IR animals needed significantly more glucose to maintain blood glucose
levels of ∼50 mg/dL in the steady state. Unfortunately, this could not be verified by the
analysis of plasma epinephrine, norepinephrine, corticosterone and glucagon levels. All
of these hormones are involved in the CRR by promoting hepatic gluconeogenesis, but
no differences could be observed in their plasma levels. Male SF-1∆IR animals showed
the same tendency towards an increased glucose infusion rate upon insulin-induced hy-
poglycemia but this did not reach statistical significance.
As already mentioned, the SF-1 Cre is expressed in approximately 50 % of the neurons
in the VMH. Thus, there might be other neurons in the VMH, that do not express the SF-1
Cre, but are responsible for the induction of the CRR. Besides insulin mediated GLUT4
expression, other factors are also involved in the CRR. A study by Fioramonti and col-
leagues indicates an important role for nitric oxide synthases in glucose-inhibited VMH
neurons for the CRR (Fioramonti et al. , 2010). Thus, other neurons in the VMH and other
glucose-sensing mechanisms might compensate for the loss of insulin signaling in SF-1
neurons and thereby still enable a sufficient induction of the counter-regulatory response
to hypoglycemia.
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Thus, the SF-1 Cre might not be the ideal tool to investigate the role of the VMH in the
CRR, but SF-1 neurons are obviously involved, as the increased GIR in female SF-1∆IR
animals indicates. Therefore it is necessary to find other marker genes for the VMH that
enables the expression of the Cre in every neuron in the VMH.
4.8 Perspectives
By the deletion of the insulin receptor in SF-1 neurons we identified insulin signaling in
the VMH as a critical component in the development of obesity. In contrast to previous
findings, where the acute role of insulin signaling in the regulation of energy homeosta-
sis was revealed, we could show that prolonged and sustained insulin signaling in VMH
SF-1 neurons contributes to the initial phase of obesity propagation. Although insulin
serves as a satiety signal in the CNS and especially in the ARC, diet-induced hyperin-
sulinemia seems to inhibit VMH SF-1 neurons in their ability to maintain body weight.
This could be shown by two different mouse models, either partially protecting from diet-
induced weight gain (SF-1∆IR) or promoting obesity under NCD conditions (SF-1∆PTEN).
However, further studies are mandatory to reveal the exact mechanism underlying the
phenotype. Due to the fact that only a part of SF-1 neurons are responsive to insulin,
further subpopulations have to be identified. Accordingly, it is still unknown how the
activity of VMH SF-1 neurons is regulated. As VMH neurons consist of glucose excited
and glucose inhibited neurons, most likely the glucose excited neurons serve as a possi-
ble candidate subpopulation that mediate the satiety promoting effects of SF-1 neurons
by glucose-stimulated glutamate-release to POMC neurons and the subsequent release
of α-MSH onto second-order neurons. Moreover, also the projection sites of SF-1 neurons
have to be identified, as a subset of SF-1 neurons is reported to express MC4R (Xu et al. ,
2003). Thus it is possible that SF-1 and POMC neurons are connected vice versa. Further-
more, recent results indicate a role for BDNF in the inhibitory input organization within
the VMH (Jo, 2012), a mechanism where insulin could also play a role.
Taken together, this study about insulin signaling in SF-1 neurons provides further in-
sights into the complex regulatory mechanism of CNS mediated control of energy home-
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ostasis and a better understanding of this regulatory network is mandatory to fight the
obesity pandemic of the 21st century.
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